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Abstract 
 
  The purpose of this study was to determine if acute exercise-induced reductions 
in pro-inflammatory cytokines contribute to exercise-induced improvements in mood in 
individuals with spinal cord injury (SCI) and multiple sclerosis (MS). Thirteen 
participants completed a single 30-minute bout of moderate-intensity exercise at 60% of 
their pre-determined VO2 peak. Mood was assessed before, immediately after, and one-
hour post-exercise, via the Profile of Mood States Questionnaire (POMS). Blood samples 
were taken before, immediately after, and one-hour post exercise, and subsequently 
analyzed for serum pro-inflammatory cytokines (IL-6, IFN-γ, and TNF-α), as well as the 
amino acids tryptophan (TRP) and kynurenine (KYN). Previous work from our lab has 
shown that chronic reductions in pro-inflammatory cytokines via diet improve mood via 
the kynurenine pathway, which is integral in serotonin production. Following the bout of 
exercise, there was a significant improvement in mood as shown by a reduction in the 
total POMS questionnaire score from pre to post-exercise (32.5±25.8 to 22.4±21.9; 
p=0.025), as well as pre to one hour post-exercise (32.5±25.8 to 21.6±25.0; p=0.008). 
Subscale analysis showed significant reductions in the Tension, Depression and Anger 
components of the POMS from pre to post-exercise and from pre to one-hour post-
exercise. Regarding pro-inflammatory cytokines, there were no exercise-induced changes 
in IL-6, but there was a significant main effect for time for TNF-α (with post-hoc 
analyses showing significant reductions from pre to one-hour post-exercise) and a trend 
for a main effect for time for IFN-γ (p=0.06). There were no changes in TRP, KYN or 
KYN/TRP. There were no correlations between changes in mood and changes in 
cytokines when all participants were analyzed. However, when considering only the 
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participants that responded to exercise with an improved mood (n=7), there were 
significant correlations between exercise-induced changes in depression and exercise-
induced changes in IL-6 (r=0.853; p=0.031) and a trend for a correlation with exercise-
induced changes in TNF-α (r=0.722; p=0.067). These results suggest that exercise-
induced changes in mood may be partially accounted for by exercise-induced changes in 
pro-inflammatory cytokines in individuals with SCI and MS, but not through a 
kynurenine pathway-dependent manner. 
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I. Introduction 
 
 
 The diagnosis of multiple sclerosis (MS) or a spinal cord injury (SCI) is a 
traumatic life altering event, requiring significant modifications in many aspects of a 
person’s life. Along with the necessary lifestyle changes, there are many alterations that 
happen within multiple systems of the body[1, 2]. As the body requires a series of bi-
directional communications within systems to sustain homeostasis, damage to one system 
can have a lasting negative effect on another. By extension, various systems can thus 
contribute to the development of a disorder.  
Neural dysfunction that accompanies MS and SCI can contribute to impairments 
within both the immune and endocrine systems. Due to the bi-directional nature of these 
communication pathways, dysfunction within the immune system can in turn have a large 
impact for further deficiencies within the neural and endocrine systems via multiple 
inflammatory mechanisms[3]. Pro-inflammatory cytokines can directly influence the 
nervous system by acting on vagal afferents, or by crossing the blood brain barrier (BBB) 
via leaky sites or specialized transporters[4]. Hormonal secretion of the hypothalamic-
pituitary-adrenal (HPA) axis can also be influenced by pro-inflammatory cytokines due to 
overstimulation of it receptors[5]. Additionally, pro-inflammatory cytokines may 
indirectly cause dysfunction within these systems by altering the regulation of enzymes; 
resulting in shifts in metabolic pathways and an imbalance of key neuroactive 
compounds[6]. Systemically elevated levels of pro-inflammatory cytokines are 
commonly referred to as chronic inflammation which can contribute to further neural, 
metabolic, and behavioural disorders[7]. This creates a vicious cycle, as these disorders 
have been shown to further contribute to elevated levels of pro-inflammatory cytokines. 
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Both MS and SCI populations have been shown to have elevated basal levels of pro-
inflammatory cytokines such as IL-1E, IL-6, IFN-J and TNF-D in comparison to able-
bodied populations, potentially contributing to the increased rates of metabolic and 
behavioural disorders within these populations[8, 9].  
 There has been consistent evidence that depressed populations demonstrate 
elevated levels of pro-inflammatory cytokines such as IL-1E, and TNF-D[10]. As MS and 
SCI populations are already exposed to elevated levels of pro-inflammatory cytokines 
due to dysfunction in other systems, they are more susceptible to depression as illustrated 
with depression rates 2-10 times higher than that of the general population[11–13]. 
Current treatment strategies for depression have been shown to be ineffective in negating 
depressive symptoms in a percentage of people, as the drug therapies typically utilized 
only address downstream targets[14]. In addition to the negative side effects that can be 
associated with these drug therapies, alternative approaches should be explored for 
addressing depression and depressed mood. 
Exercise has long been shown to be effective in reducing the secondary health 
risks associated MS and SCI[15, 16]. A single bout of moderate aerobic exercise has been 
shown to be uniquely anti-inflammatory in that it seems to bypass the traditional increase 
in pro-inflammatory cytokines seen in immune responses, and instead increase the 
production of anti-inflammatory cytokines such as IL-6, IL-10, and IL-1RA[17, 18] As 
anti-inflammatory cytokines have been shown to inhibit the production of pro-
inflammatory cytokines and indirectly affect numerous enzymes and receptors, exercise 
offers a distinctive role as a holistic means to reduce inflammation. Additionally, 
moderate intensity exercise has been consistently demonstrated to improve the mood of 
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healthy, depressed, and special populations[19–21]. Due to the established link between 
inflammation and mood in long-term exercise studies, questions arise for the prospective 
role that acute exercise-induced alterations in the anti-inflammatory environment 
contribute to mood modifications. There remains a large gap in the literature regarding 
the physiological mechanism behind the demonstrated exercise-induced mood changes in 
any population group. Therefore, the exploration of the potential acute relationship 
between exercise-induced changes in inflammation and mood is the focus of this thesis.   
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II. Literature Review 
 
2.1.0 Background and Epidemiology of Multiple Sclerosis 
2.1.1 Epidemiology and Demographics 
The incidence rate of multiple sclerosis (MS) in Canada is 240 per 100000, 
making it the highest incidence rate in the world [22]. These rates are increasing, 
especially in women [23]. Of these individuals, approximately 85% are first diagnosed 
with relapse-remitting multiple sclerosis (RRMS), meaning that they have temporary 
relapses or exacerbations of deficit with full or close to full recovery in between relapse 
periods [24].  Due to the varying size and locations of an individual’s lesions, many 
people are affected in different ways by the disease. In regards to the degree of disability, 
the progressive nature of MS results in variable symptom severity (as measured by the 
Expanded Disability Status Scale (EDSS)) throughout disease progression. Tremlett et 
al., (2006) reported that on average, MS progresses from the onset of diagnosis to an 
EDSS score of 6 over the course of 27.9 years; where a score of 6 indicates the use of a 
walking aid to walk 100m.  
 The median age of onset of the disease is 28 years, with most onsets occurring 
between the ages of 18-40 [25]. It is more commonly diagnosed in women, at a ratio of 
3:1. Despite MS being more common in women, men’s disease progression and disability 
onset tends to be more severe [26]. The mortality rates of those aged 30-39 have been 
decreasing while mortality rates in the age groups 60-69, 70-79, and 80+ have increased 
since 1975, most likely as a result of advancements in health care and health promotion 
that keep people alive after the initial diagnosis of the disease [27].  
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2.1.2 Etiology 
MS is of an unknown etiology. The leading theory into the cause of the disease is a 
combination of environmental and genetic factors. Earlier research has indicated that 
there is a positive correlation between higher MS incidence rates and the distance one 
lives from the equator. Work done by Hernàn, Olek, and Ascherio (1999) has disputed 
this correlation by attributing it to limited resources and information from the countries 
closer to the equator. While geographic latitude is no longer thought to influence the 
incidence of MS, regional variance has been shown in larger countries such as Canada 
[23, 28, 29]. 
 
2.1.3 Types of MS 
There are four distinct forms of MS, with 85% of people originally diagnosed 
with RRMS, making it the most common form of MS. RRMS is characterized by 
episodes of acute neurological deterioration called relapses, which are then followed by a 
period called remission, where there is close to a full recovery to prior relapse state and 
function.  
Over the duration of their disease, two-thirds of individuals with RRMS will 
progress into secondary progressive multiple sclerosis (SPMS) [25]. SPMS is 
characterized by steady deterioration with or without the presence of relapses or 
remissions.  
The third form of MS is primary progressive multiple sclerosis (PPMS). It rarely 
occurs, diagnosed only in 10% of all MS cases. This form of MS does not have relapses 
and remissions, but starts with a slow, progressive deterioration from the onset of 
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diagnosis. Contrary to most forms of MS, where there are higher rates in women, PPMS 
affects the sexes roughly equally[24], and the age of onset is 10 years later than the more 
common forms of MS [30]. While the age of onset for PPMS may be later in life, the 
disease progression is much faster, with this group reaching an EDSS score of 6 at a 
younger age[26].  
The final, and most rare type of MS is primary-relapsing multiple sclerosis 
(PRMS), occurring in only 5% of the MS population. The disease progression is steady 
from the beginning of the diagnosis, with clear relapses but no remission periods.  
 
2.1.4 Pathophysiology  
The pathophysiology of MS is typically associated with demyelinated lesions with 
partial axonal preservation.  Lesions can be found in the white matter of the ventricles, 
the brainstem, spinal cord, and optic nerve. MS lesion size and location vary in every 
patient, making no two cases the same. The type of MS the person has is also important 
in the pathology of the disease. Acute and relapsing types of MS have a larger 
inflammatory profile consisting of major histocompatibility complex (MHC) Class 1-
restricted CD8+ T cell expression within the lesions. The activated T cells and 
macrophages travel through the compromised blood brain barrier (BBB), which then 
target the myelin sheaths of the nerve axons [31]. 
Remyelination of these damaged sites has been seen in earlier stages of MS 
during remission periods. However, the rate of remyelination will eventually slow or stop 
all together during the progressive components of the disease. The exact cause of this 
attenuation is thought to be due to fewer oligodendrocyte progenitor cells being signaled 
  
 7 
to the demyelinated site [32]. In SPSS and PPSS the inflammatory profile is much more 
limited. Instead of an increase in new lesions and further demyelination of the white 
matter, lesions will instead slowly expand in size, damaging the surrounding areas of the 
nerve and thus causing further functional decline [31]. 
 
2.2.0 Background and Epidemiology of Spinal Cord Injury 
2.2.1 Epidemiology and Demographics 
The incidence rate of spinal cord injuries are steadily increasing, with rates of 35 
per million population in Canada [33]. The age of onset for a spinal cord injury has 
traditionally been the highest between the ages of 16-29. Recently, a second spike has 
risen for the 65+ age bracket, with many of these injuries coming due to a fall. As a result 
of this second spike, the mean age of people with a spinal cord injury has shifted from 32 
to 42 years of age between 1986-2006 [34]. Even with a shift in the average age of people 
living with SCI, young males outnumber female incidence rates at a ratio of 3:1 [34]. 
 
2.2.2 Etiology 
In Canada, motor vehicle accidents (MVA) have historically been the most 
common cause of SCI, with numbers ranging between 50-60% of all cases. Falls now 
constitute the second highest cause of SCI, and these rates are constantly increasing to the 
point where some studies rate them as more causative than MVA [33]. This is evident in 
populations over 65, as falls represent 63% of the cause of SCI in this age bracket [35]. 
Other causes of SCI such as sport injuries and injuries due to violence have been in 
decline, and only account for a combined 20% of all SCI [36].   
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2.2.3 Anatomy of the Spinal Cord 
The spinal cord is contained within the protective vertebral column and cushioned 
by the cerebral spinal fluid surrounding it. It is essential to relaying motor and sensory 
information between the brain and all parts of the body. The spinal cord is composed of 
ascending tracts that relay sensory information such as proprioception, touch, pain, and 
temperature, and descending tracts that relay motor information to efferent nerves within 
the body. The inner grey matter is composed of interneurons and neuronal cell bodies. 
The amount of white and grey matter varies depending on the spinal segment, with larger 
amounts of grey matter appearing in the cervical and lumbosacral segments [37].  
 
2.2.4 Injury Level 
In general, the level of SCI can be classified into two categories, tetraplegia and 
paraplegia. Tetraplegia results from an injury to the cervical region of the spinal cord and 
is characterized by the loss of sensory and/or motor contributions to the upper 
extremities, trunk, lower extremities, and pelvic organs. If the lesion occurs in the 
thoracic, lumbar, or sacral segments of the spinal cord, paraplegia results, which is 
characterized by normal upper extremity innervation. However, the trunk, lower 
extremities, and pelvic organs may be affected depending on the location of the lesion 
[37]. Regarding the level of injury, 40-75% are cervical injuries, 9-11% thoracic, and 10-
26% sacral-lumbar injuries [33, 38, 39]. 
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2.2.5 Severity 
There is a large range in the severity or completeness of an SCI. When there is no 
motor and sensory function at some point below the injured site, the injury is termed 
complete. Clinically, a complete injury will be determined by the absence of sensory and 
motor capabilities in the 4th and 5th sacral regions of the spinal cord. In the cases where 
there is partial motor and/or sensory function maintained, including the 4th and 5th sacral 
segments, the injury is termed incomplete. It is estimated that half of all injuries are 
incomplete, with percentages increasing due to improved health care[36, 38]. The 
concept of injury severity can be further specified with the 5-point (A-E) ASIA 
Impairment Scale (AIS; where ASIA stands for American Spinal Injury Association). 
AIS A denotes a complete injury, while AIS E denotes a SCI with full recovery of motor 
and sensory function. AIS scores of B, C, and D correspond to an incomplete injury with 
increasing sensory and motor functionality.  (See appendix for further definitions).  
 
2.3.0 Immunoregulatory Function 
2.3.1 Cytokine Production 
 Cytokines are small proteins that assist with the communication between cells for 
the purpose of immunoregulation. They can be produced within the brain, spinal cord, 
and skeletal muscle by immune cells such as T-cells and macrophages. The term cytokine 
is very broad and covers a multitude of cells that can have roles in autocrine, paracrine, or 
endocrine actions [40–43]. A single cytokine may also have pleiotropic characteristics, 
meaning that they can exert multiple actions, and are often produced in a cascade [43].  
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2.3.2 The Immune System 
The immune system comprises a large collection of cells and molecules that work 
together to defend the body from foreign pathogens. The immune system utilizes the 
complementary actions of two separate but interdependent components; the innate and 
the adaptive (or acquired) immune systems, to protect the body by identifying, attacking, 
and destroying the potentially harmful pathogens [44]. The innate system is the first line 
of defence, and it is non-specific in that it will fight pathogens in the same way, 
regardless of whether or not the system has encountered them before. If the innate system 
proves ineffective, the adaptive immune system will be activated and use pathogen-
specific strategies to attack and destroy [42].  
 
2.3.3 Innate Immunity 
The innate system is immediately activated when an infectious agent attempts to 
enter the body. All immune defenses that lack an immunologic memory are considered to 
be part of the innate immune system [45]. Cells called phagocytes, which include 
neutrophils, macrophages, and dendritic cells, engulf foreign pathogens through a process 
called phagocytosis in which the pathogen is destroyed. Another aspect of the innate 
immune system is the production of natural killer (NK) cells. Natural killer cells are 
important in the disintegration of viral and cancer cells by breaking up the cell membrane 
of these cells via pore-forming proteins [42, 45]. The innate system utilizes recognition 
molecules called toll like receptors (TLR) to sense the pathogen-associated molecular 
patterns (PAMPs) of bacteria, indicating to the system that the pathogen is foreign. 
Accordingly, there is activation of both phagocytes of the innate system, (neutrophils and 
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macrophages) cytokine production, and antigen presenting cells (APC) of the adaptive 
immune system [42, 46].  
 
2.3.4 Adaptive Immunity 
 Unlike the innate system, the adaptive immune system utilizes past experiences to 
produce specific antigens via lymphocytes to destroy invading pathogens. It can further 
be categorized into humoral or cell mediated immunity [42].  
 Humoral immunity defends the body from extracellular pathogens by the 
activation of circulating immunoglobulins. During the innate immunity response, 
phagocytes including monocytes, macrophages, and dendritic cells engulf the pathogen 
and destroy it. The activated TLRs on the surface of the antigen presenting cells stimulate 
increased expression of major histocompatibility complex (MHC) II proteins [47]. Left 
over parts of the destroyed pathogen are then accepted and they can be presented to naïve 
or memory T-cells that have never been presented with the antigen before, initializing a 
primary immune response. This causes proliferation of more T-cells that will now be able 
to recognize that specific antigen for future encounters [48]. Memory T-cells (T-cells that 
have previously encountered that specific antigen) can produce a faster, and more 
efficient secondary response. T-helper (Th) cells can coordinate this secondary response 
via the release of cytokines to activate other immune cells. This stimulates mature B cells 
to proliferate and differentiate into immunoglobulin-secreting plasma cells [48]. Both B 
and T cells circulate throughout the body to provide antigen-specific surveillance of any 
invading pathogens. While immunoglobins (or antibodies) are unable to destroy the 
antigen by themselves, they either block the toxic release of some antigens through a 
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process known as neutralization, or they provide a road-block by clumping together with 
the antigen to slow it down and will call on phagocytes to destroy the antigen in a process 
known as agglutination [42].  
If the pathogen has moved intracellularly, humoral immunity is no longer 
effective and the body must now utilize cell-mediated immunity. Cell mediated immunity 
is mediated by activated effector T cells and macrophages for intracellular pathogens and 
infected host cells. When T-helper cells bind to the MHC complex proteins of 
macrophages, a specific antigenic determinant is displayed. This stimulates the 
macrophage to release the cytokine IL-1, which then stimulates T cells to grow and 
divide. The activated T cells then release IL-2, which further aids in the growth and 
dividing of more T-helper and Tc (T-cytotoxic) cells.  The T-cytotoxic cells can 
recognize the same antigenic determinant displayed on the original MHC complex 
protein. T-cytotoxic cells will then release perforin, causing death of the infected host cell 
by lysis. The left over cell debris is then ingested and digested by phagocytes [42].  
 
2.3.5 The Inflammatory Response 
Cytokines play an important role in the body’s defense against invading 
pathogens. For both the innate and adaptive immune systems, cytokines assist with 
healing and/or preventing tissue damage by sending signals to other immune cells to 
proliferate and travel to the damaged area [40]. While the immune system is generally 
effective, an inflammatory response may occur to prevent the spreading of the pathogen 
and/or heal the affected area. Once a foreign pathogen is detected there is a release of 
histamine by mast cells in the affected area. This causes both vasodilation in surrounding 
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arterioles, which brings more blood to the affected area, and an increase in capillary 
permeability [42]. The increase in blood flow is accompanied by an influx of phagocytic 
leukocytes and plasma proteins. Externally, the increase in blood flow leads to redness 
and emitted heat from the affected area. The increased capillary permeability allows the 
protein fibrinogen into the area where it is converted into fibrin. Fibrin walls off the 
invading pathogen by forming interstitial fluid clots, which prevents the spreading of the 
pathogen and allowing time for phagocytes to arrive to the area [42]. Chemical mediators 
known as chemokines send signals to attract more phagocytes to the site, which further 
assist in the break down of the pathogen. In addition to more phagocytes being recruited 
to the affected site, new leukocytes are proliferated in the bone marrow from cytokine 
release from activated T-cells. The combination of increased recruitment and 
proliferation of phagocytes leads to the removal of the pathogen and clears the area for 
tissue repair [42].  
Cytokines can modify brain behaviour and function by hormonal and neural 
avenues, and may access the brain by travelling through leaky sites in the blood brain 
barrier (BBB) via circumventricular organs, and by using specific transporters. Cytokines 
can also communicate with the brain by acting on the vagal afferent pathways [4]. 
 
2.3.6. Cytokine Homeostasis 
Cytokines work to keep the body in immune homeostasis by both promoting and 
inhibiting other immune cells. This makes them very difficult to categorize as some have 
multiple roles, while others can be redundant in their actions [40, 41]. A common way to 
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categorize cytokines is by placing them into two categories that indicate their role in the 
inflammatory process. Pro-inflammatory cytokines promote immune responses such as 
proliferation and recruitment of immune cells in the instance of an invading foreign 
pathogen [40]. In contrast, once the pathogen is phagocytized and the healing process 
begins, anti-inflammatory cytokines are released to inhibit further production of pro-
inflammatory cytokines, and by extension, help bring cytokines back to prior levels [40]. 
This balance in cytokine levels is important for a maintained immune homeostasis, which 
is seen in healthy individuals. Many special populations, including those with MS and 
SCI may have a dysfunction in this homeostasis, which can lead to negative health 
effects.  
 
2.4.0 Immune Dysfunction & Chronic Inflammation Following MS & 
SCI  
 The complex bi-directional relationships between the nervous, endocrine and 
immune systems contribute to chronic inflammation, as dysfunction within one system 
can alter homeostasis within another. The loss of autonomic innervation of lymphoid 
organs and corresponding dysfunction in the hypothalamic-pituitary-adrenal (HPA) axis 
contribute to the higher rates of chronic inflammation in both people with MS and SCI 
[3]. It is unknown as to what system initially influences the others, but dysfunction within 
one system influences dysfunction within others, and vice-versa, thus creating a vicious 
cycle. Ultimately, the resulting inflammation accumulating in the body may lead to other 
secondary health complications, such as urinary tract infections, obesity, cardiovascular 
disease, and psychological disorders such as depression [49, 50]. 
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2.4.1 Autonomic Nerve Damage  
 The autonomic nervous system, consisting of the sympathetic and 
parasympathetic nervous systems (SNS and PNS) acts as a neuromodulator of the 
immune system in the attempt to maintain physiological homeostasis [51]. In the SNS, 
preganglionic fibres originating from the spinal cord between T1-L2 synapse in 
peripheral autonomic ganglia. Postganglionic fibres reach their effector lymphoid organs 
such as the thymus, spleen, adrenal medulla, and lymph nodes, where they release 
catecholamines, such as the neurotransmitter norepinephrine (NE) for direct 
communication with lymphocytes [52]. Catecholamines have been shown to increase the 
production of anti-inflammatory cytokines such as IL-4, which act to suppress the 
continued production of pro-inflammatory cytokines. Damage to the SNS may also 
contribute to reduced immune function due to a loss of afferent signaling from the 
adrenal gland to the hypothalamus. Impairments to this afferent pathway may reduce 
activation of the hypothalamic nuclei, which may ultimately induce dysfunction within 
the HPA axis of the endocrine system [1].  
The PNS works antagonistically to the SNS and has preganglionic fibres 
originating from the vagus nerve and the S2-S4 region of the spinal cord which synapse 
with postganglionic fibres that release acetylcholine (Ach) [51]. The PNS may have a 
role in peripheral inflammatory responses via the cholinergic anti-inflammatory pathway, 
where vagal afferent and efferent pathways contribute to inhibiting TNF-D levels [53].  
Damage to the ANS restricts the system’s ability to monitor and inhibit the 
release of pro-inflammatory cytokines such as TNF-D and IL-1E, and promote the 
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production of anti-inflammatory cytokines, as shown in both SCI and MS populations 
[54–57]. This further promotes the chronically elevated levels of circulating pro-
inflammatory cytokines within the body, potentially leading to further dysfunction within 
other systems.  
2.4.2 Endocrine Dysfunction 
The Hypothalamic-Pituitary-Adrenal (HPA) axis acts as a hormonal pathway for 
the CNS to regulate the immune system. Dysfunction of the HPA axis occurs when there 
is damage to central nervous system, causing an imbalance in the regulation of immune 
cells [5]. Corticotrophin-releasing hormone (CRH) is secreted from the hypothalamus, 
which stimulates the expression of adrenocorticotropin (ACTH) from the anterior 
pituitary gland. ACTH activates the adrenal gland and stimulates the expression and 
release of glucocorticoids, such as cortisol. Glucocorticoids modulate cytokine 
expression by suppressing the release of pro-inflammatory cytokines and upregulating 
anti-inflammatory cytokines [5]. This induces a shift from a T-1 helper (Th1) to T-2 
helper (Th2) pattern of immunity, mostly due to the downregulation of pro-inflammatory 
cytokines, which permits the dominance of Th2 anti-inflammatory cytokines to take over. 
When disruption of this pathway occurs, as in the instance of a traumatic spinal cord 
injury or multiple sclerosis, dysfunction in the HPA axis can result either in a lack of 
glucocorticoid production, or desensitization of the receptors [1, 3]. This shifts the 
immune system back from a Th2 to Th1 dominance, where the anti-inflammatory 
response in blunted and there is an increase in pro-inflammatory cytokines [58]. The 
increase in the production of pro-inflammatory cytokines and decrease in anti-
inflammatory cytokines combine to a produce a state of chronic inflammation in both 
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population groups, which can lead to other secondary health issues [8, 9, 59]. Elevated 
pro-inflammatory profiles have been found in both spinal cord injury and multiple 
sclerosis populations in comparison to control populations [8, 9]. Positive correlations 
have been shown such that the higher the SCI level, the greater the degree of pro-
inflammatory cytokines [9]. Furthermore, positive correlations have also been shown 
such that the further the disease progression in MS, the greater the degree of pro-
inflammatory cytokines [8]. Interestingly, higher levels of anti-inflammatory cytokines 
such as IL-4 and IL-10 were also found in the MS groups, possibly as a strategy to 
downregulate the elevated pro-inflammatory cytokines such as IL-1E and TNF-D.  
 
2.5.0 Depression 
2.5.1 Background 
Both the MS and SCI populations have an increased risk of depression [12, 60]. 
Depression is characterized as a mood disorder negatively affecting how one feels, 
thinks, and acts [61]. Symptoms must last for longer than two weeks and can range from 
feelings of sadness, worthlessness, anger, fatigue, suicidal tendencies, anxiety, and loss of 
enjoyment in normally pleasurable activities. 
Approximately 25% of the MS population has been reported to suffer from 
depression, with some studies reporting rates as high as 50% [12]. In the SCI population, 
depression rates have been estimated between 7-31% [60]. These rates contrast with the 
4.8% rate of depression that is typically reported in the able-bodied [62], which is a great 
concern for both population groups and calls for interventions in prevention and 
treatment for the affected people. Suicide rates are also much higher in individuals with 
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MS and SCI, as it has been reported that suicide rates are 2-7.5 times greater in people 
with MS [11] and 3-5 times greater in people with SCI in comparison to the general 
population [63, 64]. People with depressed mood may present with similar symptoms to 
clinical depression with the caveat that it does not last up to two weeks [61]. Mood, as 
opposed to emotions, are typically longer lasting and more generalizable, as they may be 
temporal with many stressors contributing to one’s overall mood [65]. Acute stressors 
such as rejection, mourning, or anxiety may help contribute to feelings of depressed 
mood [66], without it fully evolving into depression. 
Being diagnosed with MS or an SCI is a life-altering event that requires many 
lifestyle changes by the individual and his or her family. Coming to terms with one’s new 
life can influence psychological well-being on its own. However, it is important to note 
the comprehensive range of underlying mechanisms behind depression and depressed 
mood in MS and SCI populations.  
 
2.5.2 Mechanisms Underlying Depression 
Chronically elevated inflammatory profiles may lead to depressive symptoms as a 
result of cytokine influences on the neuroactive compounds of the kynurenine pathway 
(KYN) [67, 68]. This metabolic pathway, in which tryptophan (TRP) is degraded into 
other metabolites (with the end result being NAD+) [69, 70] offers a potential mechanism 
such that any dysfunction within this pathway will have important implications for 
depression and depressed mood. Tryptophan is essential for serotonin (5-HT) production 
within the brain. However, alternatively, tryptophan can also be oxidized by the enzymes 
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2,3-dioxygenase (TDO) or indoleamine 2,3-dioxygenase (IDO), to become kynurenine 
(KYN). KYN will then follow one of two pathways; the kynurenine-kynurenic acid 
(KYN-KYNA) pathway within astrocytes or the kynurenine-nicotinamide adenine 
dinucleotide (KYN-NAD) pathway, which occurs in microglia cells. Within the KYN-
KYNA pathway, KYN is acted upon by the enzyme kynurenine aminotransferase (KAT), 
where it becomes the neuroprotector kynurenic acid (KYNA). Following the KYN-NAD 
pathway, KYN is acted upon by the enzyme kynurenine 3-monooxygenase (KMO) where 
it becomes 3-hydroxykynurenine (3-HK), later to become the neurotoxin quinolinic acid 
(QUIN) and finally NAD+[69, 70]. Under normal circumstances, the kynurenine pathway 
is well regulated and a balance is found between the neuroprotector KYNA and the 
neurotoxin QUIN [69]. However, when there is an increased basal amount of pro-
inflammatory cytokines, there is a corresponding upregulation of IDO, which increases 
the rate of degradation of tryptophan to KYN, reducing the amount that will travel to the 
brain to synthesize serotonin [14]. With more tryptophan being degraded by IDO, there is 
an indirect increase in the levels of QUIN. Elevated QUIN levels cause an over-activation 
of N-methyl-D-aspartate (NDMA) receptors leading to hippocampal atrophy and HPA 
axis dysfunction [69, 70]. Atrophy within the hippocampus has shown in depressed 
populations, although if depression causes hippocampal atrophy or hippocampal atrophy 
causes depression remains inconclusive [71, 72]. While a healthy HPA axis can produce 
glucocorticoids to activate the negative feedback loop to effectively turn off further 
production from the adrenal gland, atrophy within the HPA axis may reduce this negative 
feedback loop, thus over-stimulating the HPA axis and causing dysfunction within the 
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region. Elevated levels of pro-inflammatory cytokines have been consistently found in 
people with depression[73], with these mechanisms being the potential causative link.  
An additional mechanism limiting the availability of serotonin is through the 
upregulation of serotonin transporters (SERT) by pro-inflammatory cytokines. SERT 
mediates reuptake of serotonin and helps maintain homeostasis. However, higher levels 
of pro-inflammatory cytokines such as TNF-D and IL-1E, as seen in chronically inflamed 
populations, have been shown to amplify the up-regulation of SERT proteins within the 
brain, leading to an increased reuptake of serotonin and corresponding reductions in 
extracellular concentrations [74, 75].  Lower levels of serotonin have been shown in 
depressed populations [76], making it a target within treatment interventions. When 
explored in-vitro, the additions of anti-inflammatory cytokines such as IL-4 and IL-10 
have been shown to block the reuptake of serotonin by blocking SERT proteins [77, 78] 
suggesting a potential treatment option in the treatment of depression. 
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Allison & Ditor (2014)[14] 
Figure 1: Peripheral and central kynurenine pathway interactions 
As indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are found at only 
very low concentrations within the brain, concentrations of within-brain tryptophan (TRP) and 
kynurenines are largely dependent on those from the periphery. TRP from the periphery competes 
with other large neutral amino acids (LNAA) for passage across the blood brain barrier (BBB) to 
be used in the synthesis of serotonin (5-HT). Kynurenine (KYN) and 3-hydroxykynurenine (3-
HK) are also capable of crossing the BBB whereby they participate in the production of 
kynurenic acid (KYNA) and quinolinic acid (QUIN) which do not easily cross it [14].  
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Allison & Ditor (2014) [14] 
 
Figure 2: Inflammatory mechanisms of depression  
Pro-inflammatory cytokines may contribute to depressive symptoms by means of various 
mechanisms. (1) Proinflammatory cytokines act on serotonin transporter (SERT) proteins within the 
brain causing a re-uptake of serotonin (5-HT) and corresponding reduced extracellular concentrations. 
(2) Proinflammatory cytokines up-regulate enzymes such as indoleamine 2,3- dioxygenase (IDO) and 
tryptophan 2,3-dioxygenase (TDO) resulting in reduced tryptophan (TRP) availability, ultimately 
contributing to reduced 5-HT synthesis. (3) Both 3- hydroxykynurenine (3-HK) and quinolinic acid 
(QUIN) may contribute to elevated levels of reactive oxygen species (ROS) and oxidative stress 
within the brain. (4) QUIN may induce N- methyl-D-aspartate (NMDA) over-activity thereby 
contributing to hippocampal atrophy and a loss of glucocorticoid receptors, ultimately leading to a loss 
of negative feedback and hypothalamic-pituitary-adrenal (HPA) axis over-activity [14]. 
 
When exploring the role of inflammation on acute mood states, the administration 
of an inflammatory pathogen has been shown to increase levels of pro-inflammatory 
cytokine IL-6, while simultaneously elevating negative mood states [79, 80]. By showing 
a correlation between inflammation and mood, perhaps reducing inflammation via anti-
inflammatory mechanisms will result in an improvement of acute mood states.  
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2.5.3 Treatments 
Current treatments for depression include the use of selective serotonin reuptake 
inhibitors (SSRI), which work to increase extracellular levels of serotonin by targeting 
SERT, thus inhibiting their role in serotonin reuptake [74]. The use of SSRIs can be 
effective in people with major depression, but unfortunately come with a multitude of 
side-effects in addition to only treating the downstream targets. Although effective in 
many cases of major depression due to their quick response in alleviating symptoms, 
SSRIs have been shown to be ineffective in 30% of patients [81]. This concern is 
compounded by the fact that patients who are resistant to drug therapies tend to 
demonstrate higher levels of circulating pro-inflammatory cytokines [82]. Treatments that 
target the immunologic and neurobiological mechanisms, thereby treating the upstream 
targets are still in the conceptual and pre-clinical stages [83]. Alternative treatments have 
focused on diet and exercise, as both have shown promise as non-pharmacological 
treatments for depression, and without the side-effects associated with drug therapy.  
 Regarding the use of diet, a 12 week anti-inflammatory diet has been shown to be 
effective in decreasing circulating pro-inflammatory cytokines, which in turn, correlated 
to decreases in depression and neuropathic pain in the SCI population [84]. Self-reported 
depression decreased by approximately 40% in that study, with diet-induced decreases in 
IL-1E being shown as the mediating factor. Likewise, self-reported neuropathic pain also 
decreased by approximately 40%, which correlated to diet-induced decreases in IFN-J 
and the eicosanoid PGE2.  
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2.5.4 Exercise as a Treatment Option 
Regarding the use of exercise, chronic exercise has been shown to be an effective 
alternative to drug therapies for people with major depressive disorder (MDD) [21, 85]. 
Exercise has been shown to be comparably effective in achieving remission in MDD with 
supervised or home-based exercise programs as common drug therapies [85] and more 
effective than quiet resting [21]. While a habitual exercise routine should be the goal of 
any exercise program, a single bout of exercise has also been shown to be effective in 
decreasing depressive symptoms and improving mood in able-bodied individuals [86–
89]. According to the social cognitive approach, depressed mood and depressive 
disorders such as MDD are considered to be varying intensities of the same phenomena 
[90]. Thus, the change in mood states might be relevant for depression itself; suggesting 
that repetitive experiences of mood improvements might affect depressive disorders over 
long term training studies. The anti-depressant effect of exercise is influenced by an 
individual’s starting point. Larger improvements in depressive mood are seen in those 
that have a high score for depression or negative mood at baseline [87, 91]. When 
examining the type of exercise that evokes the best response for improving mood, aerobic 
exercise is the most consistent in eliciting a positive response. An exercise duration of 10 
minutes has been shown to be enough time to improve one’s mood, however the majority 
of literature recommends 20-40 minutes of exercise to evoke the best response [91, 92]. 
The ideal intensity is also subject to debate, with most studies suggesting that low to 
moderate intensities are the most effective in improving mood. When exercising at too 
high of an intensity, negative mood states tend to increase. Therefore, it should be 
  
 25 
common practice not to exercise above one’s ability level in order to effectively modulate 
one’s mood [91–93].  
Acute exercise has also been shown to be effective in special populations for 
improving mood states [19, 94, 95], and like other populations, aerobic exercise seems to 
be the best modality. Additionally, the intensity of exercise plays a role in mood 
alterations, as working at a moderate intensity, as opposed to light and heavy intensities, 
evoked the greatest positive change in mood [19].  
While it has been shown that exercise does indeed alter mood states, the 
mechanisms behind these changes are currently unknown. There are many hypotheses, all 
with variable support. When looking at psychological reasons for these changes, 
researchers argue that increasing self-efficacy and feeling in control of one’s own 
situation is enough to elicit a positive change [90]. Others argue that this change is 
merely due to exercise acting to avert one’s focus away from their depressive thoughts 
[90]. Further research has explored hormonal, inflammatory, and neurogenesis alterations 
[96] but no research has explored any potential mechanism and their role in acute mood 
alteration. It has been shown that there is a decrease in pro-inflammatory cytokines IL-6, 
IL-8, and TNF-α and increases in the anti-inflammatory cytokine IL-4 in people with 
MDD after an acute bout of submaximal and maximal exercise [97].  
Overall, it has been shown that chronically elevated levels of inflammation can 
increase the risk of depression, while exercise seems to alleviate depression and 
depressive mood. Therefore, perhaps exercised-induced decreases in pro-inflammatory, 
or increases in anti-inflammatory cytokines mediate the exercise-induced decrease in 
depressive symptoms.  
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2.6.0 The Effect of Acute Exercise on Cytokines  
Regular exercise has consistently shown to be beneficial in preventing all-cause 
mortality, including cardiovascular disease, type 2 diabetes, obesity and hypertension 
[98]. Additionally, chronic exercise has been shown to increase anti-inflammatory 
markers and decrease pro-inflammatory cytokine levels, while a single bout of exercise 
has consistently shown to have a unique influence on the inflammatory profile [17]. 
Unlike the inflammatory response that occurs during infection where pro-inflammatory 
cytokines such as TNF-D and IL-1E are increased followed by increases in anti-
inflammatory cytokines, exercise seems to bypass the initial pro-inflammatory response 
when working at a moderate intensity. During exercise, the cytokine IL-6 is released from 
working skeletal muscle, and thus termed a myokine. IL-6, which has roles as both a pro 
and anti-inflammatory cytokine, increases dramatically with exercise intensity. The 
increase in circulating IL-6 activates the release of other anti-inflammatory cytokines 
such as IL-10, IL-1ra, and soluble TNF receptors (sTNFRs) while also inhibiting the pro-
inflammatory cytokine TNF-D [17, 99, 100]. Furthermore, with the increase of anti-
inflammatory cytokines because of the elevated IL-6 levels, there is additional inhibition 
of pro-inflammatory cytokines TNF-D, IFN-J, and IL-1E. By increasing anti-
inflammatory cytokines and decreasing pro-inflammatory cytokines, exercise may play 
an acute role in changes in both the aforementioned Kynurenine and SERT pathways. 
Elevations in anti-inflammatory cytokines may be inhibiting the production of pro-
inflammatory cytokines, indirectly reducing the activity of IDO [101]. As IDO oxidizes 
available tryptophan, reducing its activity levels will allow for more tryptophan to 
become available to be synthesized into serotonin within the brain, thus improving one’s 
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overall mood. Additionally, elevations in anti-inflammatory cytokines will inhibit SERT 
transporters to further contribute to tryptophan availability. Tryptophan availability is 
further increased as moderate acute exercise has been shown to increase nonesterified 
fatty acid (NEFA) mobilization [102]. Albumin, which typically is bound to tryptophan 
molecules, is displaced by NEFA, as NEFA wants to bind to albumin. This frees up a 
larger proportion of free form tryptophan that can then be synthesized into serotonin 
within the brain [102]. These changes are accompanied by a shift in the ratio of 
kynurenine metabolites, as there is seen to be an increase in the production of the 
neuroprotective kynurenic acid and a decline in the neurotoxic quinolinic acid 
peripherally [103, 104].  
Mechanisms that may explain these changes include the activation of the HPA 
axis and increased sympathetic neural output [100]. During exercise, there is an increased 
release of cortisol from the HPA axis and adrenaline as part of SNS activation, which 
both precede the rise in IL-6 from the skeletal muscle. These hormones both work to 
inhibit the release of the pro-inflammatory cytokine TNF-D by monocytes. Cortisol is 
also augmented by the release of IL-6, further increasing its levels and its regulatory 
effect in the body. The role of SNS activation during exercise is further supported as 
individuals with complete tetraplegia, with a blunted sympathetic response, do not have 
similar anti-inflammatory cytokine increases in circulating blood as those with an intact 
sympathetic drive [105, 106]. Thus, hormones, myokines, and cytokines all contribute to 
the anti-inflammatory effect of exercise. Other factors that may influence the exercise-
induced change in cytokine levels include the inhibition of macrophage infiltration into 
adipose tissue, and downregulation of TLRs, which both work to reduce the number of 
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pro-inflammatory monocytes in the blood. Increased levels of growth hormone, prolactin, 
and heat shock proteins that influence leukocyte trafficking may also contribute to the 
anti-inflammatory effect of exercise [99]. When compared to controls, MS and SCI 
populations not only have higher baseline pro-inflammatory profiles, but also a blunted 
exercise-induced increase in anti-inflammatory profiles [105–107]. This blunted anti-
inflammatory response may be attributed to the aforementioned dysfunction within the 
endocrine, nervous, and muscular systems.  
An alternative option to using basic aerobic exercise is the use of functional 
electrical stimulation (FES) in a hybrid format with exercise. One study has shown that 
the combined therapy is more effective in increasing anti-inflammatory markers in a 
motor complete spinal cord population [108]. While promising for motor complete SCI, 
the caveat of this type of treatment is that a major limitation for FES is skin sensitivity. 
For individuals who are hypersensitive to touch, the level of stimulation necessary to 
evoke a larger anti-inflammatory response cannot be attained. Resistance training has 
also been explored as a modality for increasing anti-inflammatory levels, however, no 
changes were found in people with MS [109]. This indicates the role that exercise 
modality plays in altering inflammation levels, as only aerobic exercise seems to have an 
influence on increasing anti-inflammatory and decreasing pro-inflammatory markers.  
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Figure 3: The proposed role of acute exercise on the kynurenine pathway 
Acute exercise may increase the release of anti-inflammatory cytokine (1), which work to 
inhibit both pro-inflammatory cytokines (2) and SERT proteins (3). Inhibiting pro-inflammatory 
cytokines indirectly reduces the amount of IDO activity and thus TRP availability. Kynurenine (4) 
will also see a shift in its metabolite ratio, with an increase in the ratio of the neuroprotective 
kynurenic acid (KYNA) instead of the neurotoxic QUIN Additionally, anti-inflammatory cytokines 
reduce SERT proteins, therefore decreasing 5-HT reuptake and resulting in more available TRP. With 
more TRP available to be synthesized into 5-HT in the brain, there should be a corresponding 
improvement in mood (5).  
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2.7.0 Conclusion 
 In conclusion, people with multiple sclerosis and spinal cord injuries have 
chronically elevated basal levels of pro-inflammatory markers. This contributes to an 
elevated risk of secondary health complications such as depression that further increases 
pro-inflammatory markers, creating a vicious cycle. As an alternative of using drug 
therapies, as they have been shown to have limitations, the utilization of moderate, acute 
exercise has been shown to both improve mood and alter cytokine profiles for a short 
period of time, but have never been examined together. By examining the potential link 
between these changes in inflammatory markers and alterations in mood, this study offers 
further evidence to the benefits of moderate exercise in combatting secondary health 
problems in special populations in addition to contributing a potential mechanism for 
exercise-invoked mood changes.  
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III. Purpose & Hypotheses 
3.1.0 Statement of Purpose 
The purpose of this study is to determine if the commonly observed acute 
exercise-induced changes in mood are related to exercise-induced changes in cytokines, 
in individuals with MS and SCI.  
 
3.2.0 Hypothesis 
Previous work in this lab has shown that improvements in mood via an anti-
inflammatory diet occurs after just 1 month. Further, pilot work that preceded this thesis 
showed that an acute bout of exercise at a moderate intensity in MS and SCI populations 
was effective in improving their mood by decreasing negative mood states (Appendix F). 
Therefore, our hypothesis is that a single bout of moderate intensity exercise will induce 
positive changes in mood in individuals with MS and SCI. Additionally, we hypothesize 
that there will be an exercise-induced increase in anti-inflammatory cytokines and a 
decrease in pro-inflammatory cytokines, and that these changes in inflammation will 
mediate the exercise-induced changes in mood via the Kynurenine pathway. 
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IV. Overview of Study Design 
4.1.0 Study Design and Participants 
 Participant recruitment occurred between January and April 2017. The study 
consisted of two exercise sessions separated by a minimum of five days. Participants with 
various levels and severities of SCI and MS were recruited for participation in the study 
from the Brock-Niagara Centre for Health and Well-Being Power Cord exercise program. 
Inclusion criteria included (1) over the age of 18, (2) SCI of any level or severity 
(American Spinal Cord Injury Association A-D) or (3) MS types of relapse-remitting or 
secondary progressive with an EDSS between 3-8 (Kurtzke Expanded Disability Status 
Score), and (4) at least 1-year post injury/diagnosis. Exclusion criteria included (1) being 
unable to fill out the questionnaires independently, (2) unstable medical condition within 
2 weeks prior to testing, and (3) currently taking anti-inflammatory medication or anti-
depressants. Participant characteristics are shown in Table 1. Thirteen individuals [3 
male, 10 female, age 57.2r7.6 years with chronic [4-42 years] MS [relapse-remitting or 
secondary progressive; EDSS 3.0-6.0] or with chronic [1-24years] SCI [C2-L2; AISA 
Impairment Scale (AIS) A-D]] were recruited for participation in the study. The study 
received ethical approval from the Brock University Research Ethics Board (File No. 16-
073 - DITOR). All data was collected on-site at Brock University and the Brock-Niagara 
Center for Health and Well-Being. 
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Table #1: Participant Characteristics 
MS/SCI TYPE EDSS/ 
AISA 
SEX AGE 
(YEARS) 
YEARS 
POST 
(YEARS) 
RELATIVE 
VO2 PEAK 
(ml/kg/min) 
MS SPMS 6.0 F 57 25 19.4 
MS RRMS 3.5 F 42 9 29.5 
MS SPMS 6.0 F 59 31 26.5 
MS SPMS 6.0 F 60 42 23.6 
MS RRMS 4.0 F 46 4 17.1 
MS SPMS 6.0 M 57 23 22.3 
MS RRMS 3.0 F 68 17 26.9 
SCI C2 D M 65 1 27.8 
SCI T3 D F 57 1 15.0 
SCI T4 A F 62 24 - 
SCI C7 A F 48 10 13.9 
SCI L2 D F 63 5 31.8 
SCI T6 A M 60 3 35.0 
AVE    57.2 15.0 24.1 
SD    7.6 13.1 6.7 
 
4.2.0 Exercise Protocol 
Visit # 1 
Participants were asked to come in in a fasted state, having abstained from 
caffeine and heavy exercise for the last 24 hours, prior to completing a VO2 peak test on a 
recumbent hybrid arm-leg ergometer (Nustep T5 Recumbent Cross Trainer; Ann Arbor, 
Michigan). Participants underwent a 5-minute warm-up at 0 resistance. Following the 
warm-up, a sealed mask, which covered their mouth and nose was secured on their face 
for the duration of the protocol. The mask measured inspired O2 levels and expired CO2 
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levels every 30 seconds using indirect calorimetry (VacuMed® Vista Mini-CPX 
metabolic cart, Ventura, CA). The test began at a low resistance, relative to a self-
selected ability level, and increased in resistance by one level every 2 minutes. 
Participants were asked to maintain a speed of 100 strides per minute (spm) for the 
duration of the protocol. The test was considered over when either the participant 
voluntarily quit, their cadence dipped below 80 spm for 3 seconds, or there was a plateau 
seen in the O2 levels inspired with increasing workloads. While undergoing the test 
protocol, the workload measured in watts (W) was recorded. The highest recorded 
inspired O2 level over a 30s-collection period was considered the participant’s VO2 peak. 
The wattage obtained during time point was used to calculate the workload of 60% VO2 
for their second session. After completing this protocol, participants completed a 5-
minute cool down at 0 resistance. 
Visit # 2 
 At least five days after completing session # 1, participants underwent 30 minutes 
of exercise at 60% of their previously determined VO2 peak on the Nustep. Prior to 
exercise, a nurse inserted an indwelling catheter into the antecubital vein of the 
participant’s non-dominant arm. A total of 15mL of blood was collected into three BD 
vacutainer serum collection tubes at baseline, which were immediately placed on ice and 
allowed to clot for 30 minutes prior to centrifugation. Participants were also asked to 
complete the 65-item Profile of Mood States (POMS) questionnaire. After a light 5-
minute warm-up on the NuStep, participants were asked to workout at 60% VO2 peak for 
30 minutes. To ensure they were working at a moderate intensity they were asked every 2 
minutes how hard they felt they are working with a 6-20 Borg Rate of Perceived Exertion 
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(RPE) Scale to ensure they did not exceed a score of 13, which is designated as 
“somewhat hard” and representative of 60% VO2 peak workload. The resistance level 
was altered accordingly to ensure they maintained a 13 RPE. Upon completion of the 30 
minutes of exercise, participants underwent a 20mL blood draw (the first 5 mL was 
discarded as per indwelling catheter guidelines) which was then placed on ice and 
allowed to clot for 30 minutes prior to centrifugation. Participants were then asked to 
complete a second POMS questionnaire. Participants were then placed in a private 
location, to avoid outside influences that may affect mood, for one hour of quiet rest after 
which the final blood draw of 20mL (first 5mL discarded) and a final POMS 
questionnaire was completed.  
 Upon completion of the exercise protocol, the blood samples were allowed to clot 
for 30 minutes followed by centrifugation at a speed of 1000 times gravity, in a 
temperature controlled centrifuge (4°C) for a duration of 15 minutes. Serum was 
separated and aliquoted at a volume of 0.5ml into individual Eppendorf tubes (to avoid 
thaw, re-freeze cycles) and frozen at -80q C until later analysis.  
 
4.3.0 Quantification of serum inflammatory markers and amino acids 
  Upon completion of the exercise protocol by all the participants, serum from each 
of the three-time points were thawed and assayed together on the same plate. 
Inflammatory mediators of interest included: pro-inflammatory cytokines TNF-D, IFN-J, 
and IL-6; anti-inflammatory cytokines IL-6; and the amino acids tryptophan (TRP), and 
kynurenine (KYN). Analysis of pro and anti-inflammatory cytokines was performed in 
triplicate via the Magpix Multiplex system (EMD Millipore, MA, U.S.A) and analyzed 
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using Luminex software. Analysis of amino acids was performed in triplicate using 
enzyme-linked immunosorbent assay (Immunodiagnostik, Bensheim, Germany; Labor 
Diagnostika, Nordhorn, Germany) Ratios for KYN/TRP was used to estimate the activity 
level of the enzyme indoleamine 2,3-dioxygenase (IDO).  
4.4.0 Assessment of Mood 
Participants were asked to complete the POMS questionnaire at each time point as 
a measure of their current mood. The POMS is a self-administered, 65-item questionnaire 
that assesses participants on six separate sub scales: tension, depression, anger, vigor, 
fatigue, and confusion [110]. Participants rated each item on a 5-point Likert scale where 
1 indicates “Not at all”, and 5 denotes a score of “Extremely.” Beginning with a base 
score of 20 to avoid any negative values, the negative subscale scores (tension, 
depression, anger, fatigue, and confusion) are added together and subtracted by the vigour 
score to form an overall measure of affect that is labeled total mood disturbance. The 
POMS has been validated as an effective method to measure acute mood changes [111]. 
 
4.5 Assessment of Inflammatory Markers 
Inflammatory mediators of interest specific to depressed mood and chronic 
inflammation included the pro-inflammatory cytokines: IL-6, TNF-D, and IFN-J[10]. 
These cytokines are known to stimulate the activity of the enzyme IDO [6]. The activity 
of IDO is of interest due its role in the breakdown of TRP into the metabolite kynurenine. 
As TRP plays a vital role as the precursor for serotonin synthesis, it was important to 
measure pre and post exercise levels. 
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Exercise has been shown to increase levels of anti-inflammatory cytokines such as IL-6 
[17]. As anti-inflammatory cytokines inhibit the production of the pro-inflammatory 
cytokines of interest, they may therefore indirectly affect the quantity and activity of 
IDO, TRP degradation, and corresponding metabolites.  
 
4.6 Statistical Analysis 
Normality was determined using the Kolmogorov-Smirnov test of normality with 
Lilliefors significance correction. A one-way repeated measures ANOVA (3 levels for 
time; baseline, immediately post, and one-hour post exercise) for blood markers of 
interest and POMS scores was performed for normally distributed data. If the data was 
not normally distributed, non-parametric analyses was performed. A Friedman’s test of 
differences among repeated measures (baseline, immediately post, 1-hour post exercise) 
was performed. If the Friedman’s test resulted in a significant value, a Wilcoxon signed-
rank test was performed to determine which time points were significantly different from 
one another.  
Finally, a Pearson’s r correlation analysis was completed to assess the relationship 
between the exercise-induced changes in cytokine markers and changes in the POMS 
questionnaire. For non-normally distributed data, a Spearman’s rank order correlation 
was performed. Statistical significance was set at p ≤ 0.05 for all tests. 
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Figure 4: Protocol Flowchart 
 
 
 
 
 
Recruitment • n = 13• 6 SCI, 7 MS
Visit #1 • VO2 Peak Test
Visit #2
•Blood draw #1 and first POMS
•30 minutes at 60% VO2 max
•Blood draw #2 and second POMS
•Quiet environment for one hour
•Blood draw #3 and final POMS
Further Analysis
•ELISA and 
Multiplex
•Scoring of POMS
•Statistical 
Analysis
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V. Results 
5.1.0 Exercise Adherence 
 All subjects successfully completed both exercise protocols in their entirety 
without any adverse events. Due to transportation issues, one participant was unable to 
complete the one-hour post-exercise measurements. Their data was thus only used for 
analysis in pre to post exercise changes for all measures.  
5.2.0 Changes in POMS 
Changes in Profile of Mood States (POMS) scores are shown in Figure 5. 
Normality was determined using the Kolmogorov-Smirnov test with Lillifors significance 
correction. The Friedman test showed that there was a statistically significant reduction in 
total mood disorder (TMD) across time points (chi-square= 8.55, p=.01). Post hoc 
analysis performed with the Wilcoxon signed-rank test showed significant reductions 
from both pre to post and pre to one hour post (z=-2.239, p=.03; z=-2.669, p=.01). When 
analyzed separately, the Friedman test showed that there was a statistically significant 
reduction across the time points in the sub-scores tension, depression, and anger (chi-
square=8.93, p=.01; chi-square=9.25, p=.01; chi-square=7.03, p=.03). Post hoc analysis 
performed with the Wilcoxon signed-rank test showed significant reductions in tension 
pre to post and pre to one hour post (z=-2.139, p=.03; z=-2.407, p=.02); significant 
reductions in depression pre to post (z=-2.036, p=.04); and significant reductions in anger 
pre to post and pre to one hour post (z=-2.375, p=.02; z=-2.025, p=.04). The Friedman 
test showed that there was no significant change in fatigue across time. One-way repeated 
measures ANOVA were performed for normally distributed sub-scores confusion and 
vigour and showed a statistically significant decline in confusion over the time points 
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(f=5.06, p=.03). Post hoc analysis performed using Bonferroni test for multiple 
comparisons showed no statically significant difference between time points, however, 
there was a trend for the reduction of confusion between pre to one hour post (T=-2.25, 
p=.06).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Change in POMS Scores across Time points 
 
5.3.0 Changes in Inflammatory Mediators 
 Changes in serum inflammatory mediators are shown in Table 2. One-way 
repeated measures ANOVA were used to measure changes in IL-6, TNF-D, and IFN-J 
across time points. There was a significant reduction in TNF-D (f=18.84, p=.01) and a 
trend for the decrease of IFN-J (f=3.68, p=.06). Further post hoc analysis with Bonferroni 
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test for multiple comparisons showed a significant reduction of TNF-D values between 
pre to one hour post (T=-3.86, p=.001) and post to one hour post (T=-2.82, p=.016). The 
analysis of the serum anti-inflammatory cytokine IL-10 was attempted, but unfortunately 
did not work due to technical difficulties. 
 
Table #2: Change in Inflammatory Mediators 
 Pre Post 1 H Post 1-Way 
ANOVA 
(p-value) 
Pre-
Post 
Pre-
1H 
Post 
Post- 
1H 
Post 
IL-6 10.13±3.31 9.51±3.03 9.91±2.91 .325     
TNF-D 25.97±8.3 24.93±7.91 23.17±6.94 .01* .151 .001* .016* 
IFN-J 40.7±13.19 37.63±11.07 38.74±11.73 .06 .227 .155 1.00 
All inflammatory mediators are displayed in pg/ml. All results are shown as mean r SD. 
All statistical analysis scores are represented as p-values. *Significantly different with 
P<0.05 
 
5.4.0 Change in Amino Acids 
 Values for serum amino acids are show in Table 3. The Friedman test showed no 
statistically significant change in kynurenine or the ratio of kynurenine to tryptophan to 
estimate IDO activity (chi-square=0.0 p=.74; chi-square=2.36, p=.307). One-way 
repeated measures ANOVA were used to measure changes in across time points for 
tryptophan. There was no statistically significant change (f=2.25, p=.13; f=0.36).  
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Table #3: Change in Amino Acids 
 Pre Post 1 H Post 1-Way 
ANOVA 
(p-value) 
Friedmans 
(p-value) 
Pre-
Post 
Pre-
1H 
Post 
Post- 
1H 
Post 
KYN 3.02r1.33 3.50r2.64 2.69r0.86  .735    
TRP 99.93r22.91 87.62r24.20 99.28r26.83 .130  .086 1.00 .516 
KYN/TRP 33.05r11.55 25.04r18.14 36.92r8.25  .307    
All amino acids are displayed in Pmol/L. All results are shown as mean r SD. All 
statistical analysis scores are represented as p-values. KYN: Kynurenine; TRP: 
Tryptophan; KYNA: Kynurenic acid. *Significantly different with P<0.05 
 
 
5.5.0 Correlations between POMS and Blood Markers 
 
Correlations between the changes in POMS scores and the changes in blood 
markers pre to post and pre to one hour post are shown in Tables 4 and 5. If the data was 
normally distributed, a Pearson’s r correlation was conducted. If the data was not 
normally distributed, a nonparametric Spearman correlation was performed. Significant 
changes were shown from pre to post changes in TNF-D and changes in pre to post 
vigour (r=-.577 p=.049). There was a significant relationship shown between changes in 
pre to one hour post scores of IFN-J  and changes in fatigue (r=-.633 p=.036). There was 
also a trend between changes in IFN-J and tension sub-scores (r=.528 p=.095) and 
changes in TNF-D with changes in tension and depression sub-scores (r=.551, p=.099; 
r=.622, p=.055). Significant relationships were shown between pre to post changes in 
tryptophan and pre to post changes in depression (r=.676 p=.011) as well as between pre 
to post changes in tryptophan and pre to post changes in vigour (r=-.577, p=0.48); there 
were trends for changes in pre to post tryptophan with pre to post changes in TMD, 
tension, and anger sub-scores (r=.519 p=.069, r=.491 p=.089, r=.481 p=.096). A trend 
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was also shown in the changing ratio of kynurenine and tryptophan to the changes in pre 
to one hour post depression (r=.505 p=.094). 
 
Table #4: Pre to Post Exercise Correlations 
 'TMD 'Tension 'Depression 'Anger 'Fatigue 'Confusion 'Vigour 
'KYN .074b -.068b .345b 0.00b .112b -.329b .171b 
'TRP .519a .491a .676a* .531b -.084a -.055b -.557a* 
'KYN/TRP .292a .360a .023a .112b .123a .370b -.306a 
'IL-6 .081a .195a .350a .081b -.209a -.053b -.044a 
'TNF-D .379a .160a .369a -.004b -.033a .167b -.577a* 
'IFN-J -.162b -.074b -.376b -.150b -.018b .371b .057b 
All correlations are represented as r-values. a represents Pearson Correlation. b 
represents Spearman’s Correlation. *Significantly correlated at P<0.05 
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Table #5: Pre to 1 Hour Post Exercise Correlations 
 'TMD 'Tension 'Depression 'Anger 'Fatigue 'Confusion 'Vigour 
'KYN -.442b -.312b -.139b -.212b -.326b -.128b .282b 
'TRP .208a .173a .728b* .031a -.039a .256a .091a 
'KYN/TRP .495b .453b .505b .286b .196b .307b -.218b 
'IL-6 .167a .323a .287a .008a -.149a .245a .072a 
'TNF-D .409a .551a .622a -.248a -.010a .431a -.076a 
'IFN-J -.087b .528b -.166b -.069b -.633b* -.189b -.077b 
All correlations are represented as r-values. a represents Pearson Correlation. b 
represents Spearman’s Correlation. *Significantly correlated at P<0.05 
 
 
5.6.0 Subgroup Analysis 
Multiple participants scored a 0 on the depression sub-score of the POMS at 
baseline, and therefore do not have the ability to improve their mood.  Further analyses 
were completed by taking a subgroup of participants who were shown to have a positive 
response to the acute bout of exercise in order to further determine if changes in mood 
scores had a relationship with the changes in blood markers. This subgroup was described 
as participants who decreased their depression sub-score by at least 2 points pre to post 
exercise as most participants had either no change in depression scores or changes of at 
least two. The resulting analysis reduced the sample size to 7 participants.   
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5.6.1 Subgroup Changes in POMS 
Changes in the subgroup’s Profile of Mood States (POMS) scores are shown in 
Figure 6. A one-way repeated measures ANOVA showed that there was a statistically 
significant reduction in TMD across time points (f= 18.53, p=.001). Post hoc analysis 
performed using Bonferroni test for multiple comparisons showed that there was a 
significant difference in the reduction of TMD between pre and post exercise (T=-18.86, 
p=.001) and pre and 1 hour post exercise (T=-18.14, p=.021). When TMD was separated 
into its sub scores, one-way repeated measures ANOVAs showed a significant difference 
between time points for tension and depression (f= 8.52, p=.02; f=19.12, p=.002) and a 
trend for vigour (f= 3.92, p=.077). Post hoc analysis performed using Bonferroni test for 
multiple comparisons showed that there was a significant difference for tension pre to 
post exercise (T=-4.71, p=.017), depression pre to post and pre to 1 hour post exercise 
time points (T=-3.7, p=.001; T=-5.00, p=.01. Friedman’s test for non-parametric data 
showed there was a significant reduction in anger and confusion across time points (chi-
square= 7.14, p=.028; chi-square= 7.76, p=.021). Post hoc analysis performed with the 
Wilcoxon signed-rank test showed significant reduction pre to post exercise in anger and 
confusion (z=-2.21, p=.027; z=-2.23, p=.021) and a trend for pre to 1 hour post exercise 
in both measures (z=-1.80, p=.072; z=-1.95, p=.051). There was also a significant 
reduction in fatigue from pre to 1 hour post exercise (z=-2.00, p=.046). 
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Figure #6: Subgroup Change in POMS Scores across Time points  
5.6.2 Subgroup Changes in Inflammatory Mediators 
 Changes in serum inflammatory mediators are shown in Table 6. One-way 
repeated measures ANOVA were used to measure changes in IL-6, TNF-D, and IFN-J 
across time points. There was a significant difference in TNF-D (f=14.8, p=.004). Post 
hoc analysis performed using Bonferroni test for multiple comparisons showed a 
significant reduction of TNF-D values between pre to post (T=-1.38, p=.043) and pre to 
one hour post exercise (T=-4.14, p=.012). There was also a trend in the reduction of TNF-
D from post to 1 hour post exercise (T=-2.76, p=0.63). There were no significant changes 
in IL-6 (f=1.14, p=.343) or IFN-J (f=. 92, p=.395) across time points.   
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Table #6: Subgroup Change in Inflammatory Mediators 
 Pre Post 1 H Post 1-Way 
ANOVA 
(p-value) 
Pre-
Post 
Pre-
1H 
Post 
Post- 
1H 
Post 
IL-6 11.14±3.89 10.10±3.76 11.23±2.93 .343    
TNF-D 29.04±6.84 27.66±6.01 24.89±6.68 .004* .043* .012* .063 
IFN-J 46.35±16.14 43.13±12.44 43.60±12.69 .395    
All inflammatory mediators are displayed in pg/ml. All results are shown as mean r SD. 
All statistical analysis scores are represented as p-values. *Significantly different with 
P<0.05 
 
5.6.3 Subgroup Change in Amino Acids 
 Changes in serum amino acids are show in Table 7. A one-way repeated measures 
ANOVA showed a significant reduction in tryptophan (f=4.87, p=.028). Post hoc analysis 
performed using Bonferroni test for multiple comparisons showed a significant difference 
in the reduction of tryptophan from pre to post exercise (T=-19.47, p=.031). No 
statistically significant changes were found for kynurenine (f=1.23, p=.333) or the 
kynurenine to tryptophan ratio across time points (chi-square=1.33, p=.513).  
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Table #7: Subgroup Change in Amino Acids 
 Pre Post 1 H Post 1-Way 
ANOVA 
(p-value) 
Friedmans 
(p-value) 
Pre-
Post 
Pre-
1H 
Post 
Post- 
1H 
Post 
KYN 2.62r1.02 2.08r0.68 2.73r1.02 .333     
TRP 106.06r28.36 86.59r28.08 94.02r26.95 .028*  .031* .281 1.00 
KYN/TRP 42.67r9.52 43.47r16.75 36.53r8.07  .513    
All amino acids are displayed in Pmol/L. All results are shown as mean r SD. All 
statistical analysis scores are represented as p-values. KYN: Kynurenine; TRP: 
Tryptophan; KYNA: Kynurenic acid. *Significantly different with P<0.05 
 
5.6.4 Subgroup Correlations between POMS and Blood Markers 
Correlations between the changes in POMS scores and the changes in blood 
markers pre to post and pre to one hour post are shown in Tables 8 and 9. Normally 
distributed data was assessed via Pearson’s r, while non normally distributed data was 
assessed via a nonparametric Spearman correlation. Significant relationships were shown 
between pre to post changes in IFN-J and changes in confusion (r=.883, p=.02) as well as 
pre to post changes in TNF-D and changes in vigour (r=-.760, p=.047). While exploring 
possible correlations between the changes between pre and 1 hour post exercise, there 
was a significant relationship between the change in IFN-J and change in tension (r=.943, 
p=.005); change in depression and IL-6 (r=.853, p=.031); and change in IFN-J and 
change in fatigue (r=-.841, p= .036). There was also a trend found for the correlation 
between the change in TNF-D and change in depression sub-scores (r=.722, p=.067). 
When looking at the correlation between mood changes and changes in amino acids 
multiple trends were shown. Trends were shown for a correlation between changes in 
TMD with changes in kynurenine and changes in the ratio of kynurenine to tryptophan 
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(r=-.783, p=.066; r=.764, p=.077). There were also trends for the correlation between 
changes in depression and kynurenine and changes in depression with the changes of the 
ratio of kynurenine to tryptophan (r=-.772, p=.072; r=.736, p=.096). Trends were seen for 
changes in anger and tryptophan, and changes in confusion and kynurenine (r=.733, 
p=.061; r=-.741, p=.092). Finally, there was a trend seen between the changes pre to 1 
hour post in TNF-D and depression (r=.722, p=0.67). 
 
Table #8: Subgroup Pre to Post Exercise Change Correlations 
 'TMD 'Tension 'Depression 'Anger 'Fatigue 'Confusion 'Vigour 
'KYN -.783b -.698b -.772b 0.00b -.029b -.741b .647b 
'TRP .374a .172a .576a .733a -.205a -.132a -.408a 
'KYN/TRP .764a .697a .736a .085a .194a .399a -.315a 
'IL-6 -.668a .285a -.166a -.406a -.595a -.310a -.013a 
'TNF-D .193a .322a -.189a .052a -.447a .334a -.760a* 
'IFN-J .696b .290b 0.00b -.203b .257b .883b* -.395b 
All correlations are represented as r-values. a represents Pearson Correlation. b 
represents Spearman’s Correlation. *Significantly different with P<0.05.  
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Table #9: Subgroup Pre to 1 Hour Post Exercise Change Correlations 
 'TMD 'Tension 'Depression 'Anger 'Fatigue 'Confusion 'Vigour 
'KYN -.414b -.018b .543b -.090b -.559b -.214b .523b 
'TRP -.090b .523b .543b -.414b -.577b -.036b -.018b 
'KYN/TRP .144b .288b .075b .198b .216b -.107b -.342b 
'IL-6 .429a .595a .853a* .059a -.239a .273a -.053a 
'TNF-D .435a .636a .722a -.400a -.095a .403a -.204a 
'IFN-J .029b .943b* .647b -.029b -.841b* -.200b .143b 
All correlations are represented as r-values. a represents Pearson Correlation. b 
represents Spearman’s Correlation. *Significantly different with P<0.05 
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VI. Discussion 
6.1.0 Major Findings 
 The current study was the first to examine the potential effects of acute exercise 
on mood and the role of cytokines as a mechanism underlying these mood changes in 
people with multiple sclerosis and spinal cord injury. The main finding from this study 
was that 30 minutes of aerobic exercise at 60% of VO2 peak is an effective means to 
improve mood in these populations. While attempting to explore a potential mechanism 
that may explain the improvements shown in mood, correlations between mood and 
blood markers were conducted for both the entire study population as well as in a sub-
group of those whose depression sub-score dropped by a minimum of 2 points with 
exercise. Due to the inconsistent correlations shown for the main group and the sub 
group, this study suggests that cytokines are probably too slow to affect mood changes 
immediately, but may instead play a limited role in maintaining the improved mood over 
a longer duration. This is suggested by the lack of correlations between changes in 
cytokines and changes in mood from pre to post exercise, but instead correlations 
appearing between pre to one hour post exercise. However, results from this study should 
be taken with caution due to its small sample size. Additionally, cytokines may not be 
acting through the Kynurenine Pathway, but instead through other mechanisms beyond 
the scope of this study.  
When exploring the changes in mood, total mood disturbance was shown to 
decline (z=-2.239, p=.03), indicating an improvement in mood, and the improved mood 
was maintained over an hour of quiet rest. Contributing to the improvement in mood, was 
the decline in tension, depression, and anger sub-scores from pre to post exercise time 
points (z=-2.239, p=.03; z=-2.036, p=.04; z=-2.375, p=.02), and these changes were 
maintained one hour post exercise. The overall exercise-induced mood enhancement that 
was suggested in this study is consistent with the literature in both able-bodied [92, 111, 
112] and special populations [19–21, 93, 113] at a moderate intensity. The results from 
the POMS questionnaire in the current study also corroborate findings in depressed 
populations from Bartholomew et al. (2005) and Meyer et al. (2016). Ensari et al (2016) 
had people with MS exercise at different intensities and saw general reductions in the 
negative sub-scores, but pre-scores began much lower than normal values, making it 
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difficult to produce any significant findings due to their lower starting point. Similarly, 
when participants began at a higher negative score, there was a greater improvement in 
mood as a result of acute exercise. 
Upon initial analysis, the change in tryptophan appeared to a have role in the 
change in mood as both significant correlations and trends for many of the mood sub-
scores pre to post exercise were found. However, all relationships except for the trend 
between the change in tryptophan and change in anger sub-score were lost in the 
subgroup analysis. A significant correlation that remained in both groups was the 
negative correlation between TNF-D and vigour, where a decrease in TNF-D led to an 
increase in vigour. There are no known studies that have linked TNF-D with vigour, 
however high levels of TNF-D are generally seen in depressed populations [70, 83], who 
are shown to also have lower levels of vigour [86] which may explain this relationship. 
The subgroup also showed trends for positive correlations between the ratio of 
kynurenine to tryptophan, an indication of IDO activity, and changes in TMD and 
depression indicating that higher IDO activity is associated with a higher TMD and 
depression score, which is consistent with the literature [67]. Finally, there was a 
significant positive correlation between changes in IFN-J and confusion, which is 
consistent with one other study that has made a link between delirium and high levels of 
IFN-J [114].  
Of the blood markers of interest, tryptophan and TNF-D were the only ones to 
significantly decrease with exercise in the subgroup of participants whose depression sub-
score decreased (z=-19.47, p=.031; z=-1.38, p=.043). Additionally, TNF-D further 
decreased from pre to 1 hour post exercise (z=-4.15, p= .012). The reduction in total 
tryptophan levels are comparable to the decline in tryptophan levels that have been seen 
in high intensity exercise [104, 115], however, it has also been shown that free 
tryptophan, or tryptophan that is no longer bound to albumin, does indeed increase with 
moderate exercise [102, 116, 117], which is a greater indicator for tryptophan’s ability to 
be synthesized into serotonin. Competition for transport across the BBB with other large 
neutral amino acids (LNAA) may also influence the amount of serotonin that is able to be 
synthesized in the brain [102, 117]. Calculating the changing ratio between TRP and 
LNAA allows for the estimation of tryptophan being transferred into the brain. The 
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reduction in TNF-D is consistent with moderate intensity exercise studies with values 
either declining or being maintained [105, 107, 118, 119]; high intensity exercise that 
may cause muscle damage has been shown to increase levels of TNF-D [18, 97, 99]. 
The fact that IL-6 levels did not change with exercise goes against the majority of 
exercise literature, with expected increases ranging from a two to 100-fold increase 
depending on exercise intensity [99, 120]. It is generally seen even in MS and SCI 
populations [9, 107], albeit with smaller increases compared to a healthy population. The 
lack of response in this study may be due to the combined effect of cytokine blunting in 
the special populations in addition to the intensity of the exercise protocol not being 
sufficient to alter cytokine profiles [121, 122]. The lack of IL-6 response may also 
explain the lack of changes in other inflammatory blood markers, as IL-6 is known to be 
a precursor to alterations in other cytokines and amino acids downstream [17].  
Pre to one hour post correlations exhibited more consistent relationships between 
changes in cytokines and changes in mood scores, as a significant positive correlation 
was found between IL-6 and depression in the sub-group, as well as positive trends in 
both groups for changes in TNF-D and depression. Other significant negative correlations 
that were found were between IFN-J and tension and fatigue sub-scores, with IFN-J and 
fatigue correlations significant for both groups, which has previously been found in MS 
populations [123].  
 
6.2.0 Clinical/ Physiological Significance 
This study suggests that a single bout of moderate intensity exercise for 30 
minutes is sufficient to improve the mood of people living with multiple sclerosis and 
spinal cord injuries and this improved mood may be maintained for at least an hour. By 
successfully improving someone’s mood after just a single bout, exercise can be used as a 
prescription to reduce negative mood symptoms for a short period of time. An 
accumulative effect of multiple bouts of exercise may then be attainable to decrease not 
just negative and depressive mood, but as a treatment consideration for people who are 
depressed. The fact that both populations are 2-10 times more likely to suffer from 
depression signifies the importance of finding alternative methods to treating depressed 
mood before it develops into depression. A single bout of moderate intensity exercise is a 
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holistic option to be paired with drug therapies that may be prescribed, contributing to 
mounting evidence on the many benefits of exercise.    
This thesis aimed to explore the potential mechanisms behind the commonly 
observed exercise-induced changes in mood in chronically inflamed populations. Two 
blood markers in particular were shown to change with acute exercise, tryptophan and 
TNF-D. Although tryptophan levels did decrease, it is difficult to make any sweeping 
conclusions, as the amount of total tryptophan does not account for the amount of free 
tryptophan in the blood [116]. Tryptophan at rest is largely bound to albumin, and 
therefore not able to be synthesized into serotonin within the brain. However, acute 
exercise has been shown to elevate free tryptophan in the brain through lipolysis via 
direct measurements in rat models [117], as well as indirect measurements in humans by 
exploring ratios of total tryptophan with other competing amino acids such as leucine and 
tyrosine [124]. Lipolysis rates increase with sustained exercise, where elevated levels of 
free fatty acids are released into the blood and displaces the binding of tryptophan to 
albumin, further elevating levels of free tryptophan [103, 117]. Therefore, even with the 
correlations with the whole sample between changes in tryptophan and negative mood 
sub-scores pre to post exercise, more analysis needs to be done to see if there is an 
increase in free tryptophan, and if this is correlated to these mood changes. Although the 
raw score for the ratio between kynurenine and tryptophan did not change with exercise, 
there was a trend for a correlation between a change in the ratio and changes in overall 
mood and depression, consequently signifying that a higher IDO expression leads to a 
higher depression score and a more negative mood. Due to the raw scores not changing, 
this may indicate that other mechanisms are in play. 
As an alternate mechanism to changes in amino acids influencing acute mood 
changes after exercise there is the possibility that cytokines are impacting mood by acting 
on sites outside the kynurenine pathway. The only cytokine with both significant changes 
and at least a trending relationship to mood pre to post exercise was TNF-D. Higher 
levels of TNF-D have been shown in people with depression [10, 68, 125, 126] and when 
injected it has been shown to increase depressive symptoms [127]. This study showed 
that TNF-D decreased with exercise, indicating that there is an upstream action 
influencing this decline. TNF-D is locally released from monocytes, macrophages, and 
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adipose tissue and it has been shown to stimulate circulating IL-6, which in turn can 
stimulate various pro and anti-inflammatory responses [100, 120]. One of the responses is 
an increase in the anti-inflammatory cytokine IL-10, which in turn inhibits further 
production of TNF-D [128] and thus potentially explains the decline that was shown. Yet, 
while TNF-D was shown to decrease with exercise there was no change in IL-6 levels. It 
is possible that IL-6 levels were elevated within skeletal muscle, as more substantial 
elevations than that of serum have been shown in response to exercise [129]. If IL-6 was 
elevated in skeletal muscle it may explain the decline in TNF-D. However, the 
measurements of skeletal muscle IL-6 was beyond the scope of this study. An alternative 
inhibitor that may have been acting on TNF-D are the increases in cortisol and 
epinephrine. While this study did not measure these hormones, both have been shown to 
increase with exercise [100] and have an inhibiting effect on TNF-D [118, 130].  
In regard to cytokines, the majority of correlations that were found in the sub-
group between the pro-inflammatory cytokines and mood changes happened between pre 
to 1 hour post exercise. IL-6, IFN-J, and TNF-D all had significant or trending 
correlations with tension or depression sub-scores during this time frame which suggests 
that cytokines are too slow to affect mood immediately, but instead play a role in 
maintaining a more positive mood afterwards. For these reasons, cytokines may still play 
a role in alterations of mood, but a much larger contributing physiological mechanism, 
such as cytokines acting on SERT proteins, remains evasive.  
 It may even be true that that are no physiological changes that are mediating 
mood, but instead it is purely psychological.  Researchers argue that exercise may just 
serve as a distraction from other stressors in an individual’s life [131, 132]. Another 
hypothesis is that exercise improves a person’s mood because they feel in control of their 
life by doing it. Increasing one’s self-efficacy may be enough to influence a positive 
mood change [112]. 
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6.3.0 Limitations 
Several limitations were apparent in this current study. First, the study was limited 
by lacking an able-bodied control group to compare with the chronically inflamed group. 
An able-bodied control group, could have assisted in establishing if the intensity of the 
exercise was sufficient to evoke a cytokine response or if the chronically inflamed 
populations had a blunted cytokine and amino acid response to the exercise session. Both 
the former and the latter would indicate that inflammatory blood markers may not play 
any role in acute mood changes if one of the groups had changes in inflammatory 
markers while both groups equally improved their moods from baseline.  
Second, having subjects exercise at only a single intensity, means there is no way 
of knowing if the cytokine response is intensity-dependent and it if that has any bearing 
on mood changes. Multiple studies have explored the variance in cytokines and intensity 
[122] and changes in mood and intensity in aerobic exercise [93, 111, 133], but none 
have combined the two. By undergoing aerobic exercise at multiple intensities, the 
establishment of how variations in changing moods may be mediated by cytokine 
alterations may be achieved.  
Third, as discussed in the future directions section, the lack of anti-inflammatory 
cytokines in this thesis make it difficult to conclude if these cytokines play a role in 
acutely improving mood through moderate intensity exercise.  
Fourth, this study attempted to measure the anti-inflammatory cytokine IL-10 as 
well as the pro-inflammatory cytokine IL-1β but the data was not obtained due to 
technical difficulties.   
Finally, the smaller sample size may have restricted the study’s ability to obtain 
significant changes because of the high standard deviations amongst the group. While the 
sample size is normal for exercise in special populations, adding additional participants 
into a future study could strengthen the relationships that may exist between mood 
changes due to exercise and the inflammatory mechanisms behind them. 
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6.4.0 Future Directions 
This study shows that moderate aerobic exercise is sufficient to evoke a positive 
change in mood in chronically inflamed populations. Correlations between mood sub-
scores and cytokines, but not amino acids, indicate that cytokines may play a role in acute 
mood alterations due to exercise, but do not appear to act through the Kynurenine 
Pathway. Therefore, future research should explore other potential physiological 
mechanisms that may be facilitating these changes.  
Other potential mechanisms that could play a role in these changes may include 
exercise induced changes in SERT transporters, endocannabinoids, anti-inflammatory 
cytokines, and the changing ratio of neuroprotective kynurenic acid to kynurenine.  
First, SERT proteins increase reuptake of serotonin after release and have been 
shown to be upregulated by pro-inflammatory cytokines such as TNF-D and IFN-J. This 
causes lower levels of extracellular serotonin in the brain. As SERT has been shown to be 
downregulated by anti-inflammatory cytokines such as IL-10 and IL-4 [77, 78], it is 
possible that decrements in levels of pro-inflammatory cytokines that were seen with 
TNF-D and the potential increase in anti-inflammatory cytokines due to acute exercise 
may decrease the rate of reuptake by SERT transporters and lead to an overall increase in 
serotonin within the brain and by extension, an improvement in mood. Future research 
should explore the relationship between acute exercise, SERT, and mood changes.  
Second, future research should further explore the role of endocannabinoids and 
their influence on mood alterations. Traditionally it has been well-accepted that the 
increase in β-endorphin levels during exercise was the mechanism behind the common 
analgesic effects and elevated mood that has been shown in the literature. However, it has 
since been shown that this is not the case, as endorphins are unable to cross the BBB and 
therefore do not act centrally. [134]. An alternative explanation to this phenomenon are 
endocannabinoids, which use similar receptors. Anandamide, a fatty acid derivative, is 
the main endocannabinoid that binds to central CB1 and peripheral CB2 receptors, and 
can pass through the BBB (and therefore act centrally), as it is lipophilic. These receptors 
also have a high affinity for the psychoactive component of marijuana, THC. 
Endocannabinoid levels have been shown to increase after acute exercise [134–136] in an 
intensity-dependent manner [137]. Anandamide has been shown to be positively 
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correlated to changes in BDNF during acute exercise. As BDNF contributes to 
neurogenesis within the hippocampus in chronic exercise, and with the anti-depressant 
effect of acute exercise [136]. Further research is required to determine if exercise-
induced changes in anandamide exist in those with SCI and MS, and if so, whether or not 
said changes account for the exercise-induced changes in mood. 
Third, while this study did not show any significant changes in kynurenine levels 
with exercise, it is possible that while the levels of kynurenine remained unchanged, the 
ratio between the neuroprotective and neurotoxic alternative pathways may have shifted 
towards the neuroprotective pathway. The final product of the neuroprotective pathway is 
kynurenic acid. Aerobic exercise has been shown to stimulate PGC-1α1 expression from 
skeletal muscle [103, 104]. PGC-1α1 has also been shown to increase the expression of 
the enzyme kynurenine aminotransferase (KAT), thereby shifting the pathway towards 
kynurenic acid production. This shift would be considered neuroprotective since 
kynurenic acid is an NMDA receptor antagonist and thus a protector against stress 
induced depression. Further research should explore the ratio change of KYN: KYNA 
and its relationship with mood improvements after moderate exercise.   
Fourth, this study did not measure changes in any anti-inflammatory cytokines. It 
is possible that instead of a correlation between improved mood and a decline in pro-
inflammatory cytokines and amino acids, the role of increasing anti-inflammatory 
cytokines with exercise may be correlated the mood improvement that was shown in this 
study. Exercise has a unique anti-inflammatory profile distinctive from that of sepsis, in 
that there is not a rise in pro-inflammatory cytokines, but instead an increase in anti-
inflammatory cytokines such as IL-6, IL-10, and IL-1ra [100, 120]. These cytokines work 
to inhibit the release of pro-inflammatory cytokines and may play a larger role in the 
improvement of mood and therefore should be examined in future analyses.  
Fifth, future researchers should also explore the differences between able-bodied 
and chronically inflamed populations and how they each respond to moderate, aerobic 
exercise. Dysfunction within multiple systems that may be apparent in chronically 
inflamed populations could play a role in physiological differences that occur during 
exercise that explain why healthier populations may improve their mood more 
consistently than chronically inflamed populations.   
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In conclusion, there are many other potential physiological mechanisms that may 
contribute to the observed mood changes with exercise. They may all play some small 
role in contributing to these changes, but until these studies are completed and repeated, 
they will remain only hypotheses.  
 
6.5.0 Conclusion  
 The current study was the first to examine the potential effects of acute exercise 
on mood and the role of cytokines as a mechanism accounting for the mood changes in 
people with multiple sclerosis and spinal cord injury. The results provided evidence that 
moderate exercise is sufficient in improving the mood in these populations. It appears 
that the Kynurenine Pathway does not play a role in exercise induced mood 
improvements, but a decline in pro-inflammatory cytokines may assist in the maintenance 
of a positive mood. Therefore, future research is warranted to explore the potential 
cytokine-related physiological mechanisms that may contribute to alterations in mood 
due to moderate intensity exercise. 
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78.  Mössner, R., Daniel, S., Schmitt, A., Albert, D., Lesch, K. (2001). Modulation of 
Serotonin Transporter Function by interleukin-4. Life Sciences, 68, 873–880. 
  
 71 
79.  Harrison, N. A., Brydon, L., Walker, C., Gray, M. A., Steptoe, A., & Critchley, H. 
D. (2009). Inflammation Causes Mood Changes Through Alterations in Subgenual 
Cingulate Activity and Mesolimbic Connectivity. Biological Psychiatry, 66(5), 
407–414. doi:10.1016/j.biopsych.2009.03.015 
80.  Wright, C. E., Strike, P. C., Brydon, L., & Steptoe, A. (2005). Acute inflammation 
and negative mood: Mediation by cytokine activation. Brain, Behavior, and 
Immunity, 19(4), 345–350. doi:10.1016/j.bbi.2004.10.003 
81.  Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., 
Warden, D., … Fava, M. (2006). Acute and longer-term outcomes in depressed 
outpatients requiring one or several treatment steps: A STAR*D report. American 
Journal of Psychiatry, 163(11), 1905–1917. doi:10.1176/appi.ajp.163.11.1905 
82.  Fitzgerald, P., O’Brien, S. M. S. S. M., Scully, P., Rijkers, K., Scott, L. V, & 
Dinan, T. G. (2006). Cutaneous glucocorticoid receptor sensitivity and pro-
inflammatory cytokine levels in antidepressant-resistant depression. Psychological 
medicine, 36(1), 37–43. doi:10.1017/S003329170500632X 
83.  Felger, J. C., & Lotrich, F. E. (2013). Inflammatory Cytokines in Depression: 
Neruobiological Mechanisms and Therapeutic Implications. Neuroscience, (246), 
199–229. doi:10.1016/j.neuroscience.2013.04.060.Inflammatory 
84.  Allison, D. J., & Ditor, D. S. (2015). Targeting inflammation to influence mood 
following spinal cord injury: a randomized clinical trial. Journal of 
neuroinflammation, 12, 204. doi:10.1186/s12974-015-0425-2 
85.  Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., Hoffman, B. M., Barbour, 
K. A., Herman, S., … Sherwood, A. (2009). Exercise and Pharmacotherapy in the 
  
 72 
Treatment of Major Depressive Disorder. Psychosomatic Medicine, 69(7), 587–
596. doi:10.1097/PSY.0b013e318148c19a.Exercise 
86.  Bartholomew, J. B., Morrison, D., Ciccolo, J. T., Berger, B. G., Motl, R. W., 
Bodin, T., … Hemsley, D. R. (1996). Neurobiological effects of exercise on major 
depressive disorder: A systematic review. Personality and Individual Differences, 
67(4), 2032–2037. doi:10.1016/j.beth.2016.04.003 
87.  Bodin, T., & Martinsen, E. W. (2004). Mood and Self-Efficacy During Acute 
Exercise in Clinical Depression. A Randomized, Controlled Study. Journal of 
Sport & Exercise Psychology, 26(4), 623. Retrieved from 
http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=15211763&site
=ehost-live 
88.  Ensari, I., Motl, R. W., & Pilutti, L. A. (2014). Exercise training improves 
depressive symptoms in people with multiple sclerosis: Results of a meta-analysis. 
Journal of Psychosomatic Research, 76(6), 465–471. 
doi:10.1016/j.jpsychores.2014.03.014 
89.  Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & 
Stubbs, B. (2016). Exercise as a treatment for depression: A meta-analysis 
adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51. 
doi:10.1016/j.jpsychires.2016.02.023 
90.  Maddux, J. E., & Meier, L. J. (1995). Self-efficacy and depression. 
91.  Yeung, R. R. (1996). Review the Acute Effects of Exercise on Mood State. 
Journal of psychosomatic research, 40(2), 123–141. doi:10.1016/0022-
3999(95)00554-4 
  
 73 
92.  Reed, J., & Ones, D. S. (2006). The effect of acute aerobic exercise on positive 
activated affect: A meta-analysis. Psychology of Sport and Exercise, 7(5), 477–
514. doi:10.1016/j.psychsport.2005.11.003 
93.  Meyer, J. D., Koltyn, K. F., Stegner, A. J., Kim, J. S., & Cook, D. B. (2016). 
Influence of Exercise Intensity for Improving Depressed Mood in Depression: A 
Dose-Response Study. Behavior Therapy, 47(4), 527–537. 
doi:10.1016/j.beth.2016.04.003 
94.  Dalgas, U., Stenager, E., Sloth, M., & Stenager, E. (2015). The effect of exercise 
on depressive symptoms in multiple sclerosis based on a meta-analysis and critical 
review of the literature. European Journal of Neurology, 22(3), 443-e34. 
doi:10.1111/ene.12576 
95.  Ginis, K. A. M., Hicks, A. L., Latimer, A. E., Warburton, D. E. R., Bourne, C., 
Ditor, D. S., … Wolfe, D. L. (2011). The development of evidence-informed 
physical activity guidelines for adults with spinal cord injury. Spinal cord, 49(11), 
1088–1096. doi:10.1038/sc.2011.63 
96.  Schuch, F. B., Deslandes, A. C., Stubbs, B., Gosmann, N. P., Silva, C. T. B. da, & 
Fleck, M. P. de A. (2016). Neurobiological effects of exercise on major depressive 
disorder: A systematic review. Neuroscience and Biobehavioral Reviews, 61, 1–
11. doi:10.1016/j.neubiorev.2015.11.012 
97.  Hallberg, L., Janelidze, S., Engstrom, G., Wisén, A. G. M., Westrin, Å., & 
Brundin, L. (2010). Exercise-induced release of cytokines in patients with major 
depressive disorder. Journal of Affective Disorders, 126(1–2), 262–267. 
doi:10.1016/j.jad.2010.02.133 
  
 74 
98.  Warburton, D. E. R., Nicol, C. W., & Bredin, S. S. D. (2006). Health benefits of 
physical activity: the evidence. CMAJ : Canadian Medical Association journal = 
journal de l’Association medicale canadienne, 174(6), 801–9. 
doi:10.1503/cmaj.051351 
99.  Pedersen, B. K., & Hoffman-Goetz, L. (2000). Exercise and the immune system: 
regulation, integration, and adaptation. Physiological reviews, 80(3), 1055–1081. 
doi:IIE0007 
100.  Gleeson, M., Bishop, N. C., Stensel, D. J., Lindley, M. R., Mastana, S. S., & 
Nimmo, M. A. (2011). The anti-inflammatory effects of exercise: mechanisms and 
implications for the prevention and treatment of disease. Nature reviews 
Immunology, 11(9), 607–615. doi:10.1038/nri3041; 10.1038/nri3041 
101.  Fujigaki, H., Yamamoto, Y., & Saito, K. (2017). L-Tryptophan-kynurenine 
pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on 
cell type differences. Neuropharmacology, 112, 264–274. 
doi:10.1016/j.neuropharm.2016.01.011 
102.  Fernstrom, J. D., & Fernstrom, M. H. (2006). Exercise, Serum Free Tryptophan, 
and Central Fatigue. Brain, (1), 544–547. 
103.  Schlittler, M., Goiny, M., Agudelo, L. Z., Venckunas, T., Brazaitis, M., Skurvydas, 
A., … Andersson, D. C. (2016). Endurance exercise increases skeletal muscle 
kynurenine aminotransferases and plasma kynurenic acid in humans. Am J Physiol 
Cell Physiol, ajpcell 00053 2016. doi:10.1152/ajpcell.00053.2016 
104.  Mudry, J.M., Alm, P.S., Erhardt, S., Goiny, M., Fritz., T., Caidahl, K., Zierath, 
J.R., Krook, A., Wallberg-Henriksson, H. (2016). Direct effects of exercise on 
  
 75 
kynurenine metabolism in people with normal glucose tolerance or type 2 diabetes. 
Diabetes/Metabolism Research and Reviews, 32(30), 754–761. doi:10.1002/dmrr 
105.  Paulson, T. A. W., Goosey-Tolfrey, V. L., Lenton, J. P., Leicht, C. A., & Bishop, 
N. C. (2013). Spinal cord injury level and the circulating cytokine response to 
strenuous exercise. Medicine and Science in Sports and Exercise, 45(9), 1649–
1655. doi:10.1249/MSS.0b013e31828f9bbb 
106.  Neefkes-Zonneveld, C. R., Bakkum, A. J., Bishop, N. C., Van Tulder, M. W., & 
Janssen, T. W. (2015). Effect of long-term physical activity and acute exercise on 
markers of systemic inflammation in persons with chronic spinal cord injury: A 
systematic review. Archives of Physical Medicine and Rehabilitation, 96(1), 30–
42. doi:10.1016/j.apmr.2014.07.006 
107.  Castellano, V., Patel, D., & White, L. (2008). Cytokine responses to acute and 
chronic exercise in multiple sclerosis. Journal of Applied …, 104, 1697–1702. 
doi:10.1152/japplphysiol.00954.2007. 
108.  Paulson, T. a W., Bishop, N. C., Smith, B. M., & Goosey-Tolfrey, V. L. (2014). 
Inflammation-mediating cytokine response to acute handcycling exercise 
with/without functional electrical stimulation-evoked lower-limb cycling. Journal 
of rehabilitation research and development, 51(4), 645–54. 
doi:10.1682/JRRD.2013.08.0184 
109.  Kjolhede, T., Dalgas, U., Gade, A. B., Bjerre, M., Stenager, E., Petersen, T., & 
Vissing, K. (2015). Acute and chronic cytokine responses to resistance exercise 
and training in people with multiple sclerosis. Scand J Med Sci Sports, 1–11. 
doi:10.1111/sms.12504 
  
 76 
110.  Mcnair, P.M., Lorr, M., Droplement, L. F. (1971). Profile of mood states manual, 
(1), 29–30. 
111.  Berger, B. G., & Motl, R. W. (2000). Exercise and mood: A selective review and 
synthesis of research employing the profile of mood states. Journal of Applied 
Sport Psychology, 12(1), 69–92. doi:10.1080/10413200008404214 
112.  Szabo, A. (2003). Acute psychological benefits of exercise performed at self-
selected workloads: implications for theory and practice. Journal of sports science 
& medicine, 2(3), 77–87. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/24627659%5Cnhttp://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=PMC3942640 
113.  Petruzzello, S. J., Snook, E. M., Gliottoni, R. C., & Motl, R. W. (2009). Anxiety 
and mood changes associated with acute cycling in persons with multiple sclerosis. 
Anxiety, Stress, and Coping, 22(3), 297–307. doi:10.1080/10615800802441245 
114.  Adamis, D., Lunn, M., Martin, F. C., Treloar, A., Gregson, N., Hamilton, G., & 
Macdonald, A. J. D. (2009). Cytokines and IGF-I in delirious and non-delirious 
acutely ill older medical inpatients. Age and Ageing, 38(3), 326–332. 
doi:10.1093/ageing/afp014 
115.  Strasser, B., Geiger, D., Schauer, M., & Gatterer, H. (2016). Effects of Exhaustive 
Aerobic Exercise on Tryptophan-Kynurenine Metabolism in Trained Athletes, 1–
10. doi:10.1371/journal.pone.0153617 
116.  Badawy, A. A. (2015). Tryptophan Availability for Kynurenine Pathway 
Metabolism across the Life span: Control Mechanisms and Focus on Aging, 
Exercise, Diet and Nutritional Supplements. Neuropharmacology, 112, 248–263. 
  
 77 
doi:10.1016/j.neuropharm.2015.11.015 
117.  Chaouloff, F. (1997). Effects of acute physical exercise on central serotonergic 
systems. Medicine & Science in Sports & Exercise, 29(1), 58–62. 
118.  Dimitrov, S., Hulteng, E., & Hong, S. (2016). Inflammation and exercise: 
inhibition of monocytic TNF production by acute exercise via β2-adrenergic 
activation. Brain, Behavior, and Immunity, 61, 60–68. 
doi:10.1016/j.bbi.2016.12.017 
119.  Perandini, L. A., Oliveira, S. D., Mello, S. B. V, Camara, N. O., Benatti, F. B., 
Lima, F. R., … Gualano, B. (2015). Inflammatory cytokine kinetics to single bouts 
of acute moderate and intense aerobic exercise in women with active and inactive 
systemic lupus erythematosus. Exercise Immunology Review, 21, 174–185. 
120.  Petersen, A. M. W., & Pedersen, B. K. (2005). The anti-inflammatory effect of 
exercise. Journal of Applied Physiology, 98(4), 1154–1162. 
doi:10.1152/japplphysiol.00164.2004. 
121.  Kouda, K., Furusawa, K., & Sugiyama, H. (2012). Does 20-min arm crank 
ergometer exercise increase plasma interleukin-6 in individuals with cervical 
spinal cord injury ?, 597–604. doi:10.1007/s00421-011-2004-2 
122.  Peake, J. M., Suzuki, K., Hordern, M., Wilson, G., Nosaka, K., & Coombes, J. S. 
(2005). Plasma cytokine changes in relation to exercise intensity and muscle 
damage. European Journal of Applied Physiology, 95(5–6), 514–521. 
doi:10.1007/s00421-005-0035-2 
123.  Pokryszko-Dragan, A., Frydecka, I., Kosmaczewska, A., Ciszak, L., Bilińska, M., 
Gruszka, E., … Frydecka, D. (2012). Stimulated peripheral production of 
  
 78 
interferon-gamma is related to fatigue and depression in multiple sclerosis. 
Clinical Neurology and Neurosurgery, 114(8), 1153–1158. 
doi:10.1016/j.clineuro.2012.02.048 
124.  Melancon, M. O., Lorrain, D., & Dionne, I. J. (2012). Exercise increases 
tryptophan availability to the brain in older men age 57-70 years. Medicine and 
Science in Sports and Exercise, 44(5), 881–887. 
doi:10.1249/MSS.0b013e31823ede8e 
125.  Rethorst, C. D., Toups, M. S., Greer, T. L., Nakonezny, P. A., Carmody, T. J., 
Grannemann, B. D., … Trivedi, M. H. (2013). Pro-inflammatory cytokines as 
predictors of antidepressant effects of exercise in major depressive disorder. 
Molecular psychiatry, 18(10), 1119–24. doi:10.1038/mp.2012.125 
126.  Liu, Y., Ho, R. C. M., & Mak, A. (2012). Interleukin (IL)-6, tumour necrosis 
factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in 
patients with major depressive disorder: A meta-analysis and meta-regression. 
Journal of Affective Disorders, 139(3), 230–239. doi:10.1016/j.jad.2011.08.003 
127.  Dantzer, R., Connor, J. C. O., Freund, G. G., Johnson, R. W., & Kelley, K. W. 
(2008). From inflammation to sickness and depression: when the immune system 
subjugates the brain. Nature Reviews. Neuroscience, 9(1), 447–453. 
doi:10.1038/nrn2297.From 
128.  Elenkov, I. J., & Chrousos, G. P. (2002). Stress hormones, proinflammatory and 
antiinflammatory cytokines, and autoimmunity. Annals of the New York Academy 
of Sciences, 966(1), 290–303. doi:10.1111/j.1749-6632.2002.tb04229.x 
129.  Peake, J. M., Della Gatta, P. A., Suzuki, K., & Nieman, D. C. (2015). Cytokine 
  
 79 
expression and secretion by skeletal muscle cells: regulatory mechanisms and 
exercise effects. Exercise Immunology Reviews, 21(1), 8–25. 
130.  van der Poll, T., Coyle, S. M., Barbosa, K., Braxton, C. C., & Lowry, S. F. (1996). 
Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 
production during human endotoxemia. The Journal of clinical investigation, 
97(3), 713–9. doi:10.1172/JCI118469 
131.  Craft, L. L., & Perna, F. M. (2004). The Benefits of Exercise for the Clinically 
Depressed. Primary care companion to the Journal of clinical psychiatry, 6(3), 
104–111. doi:10.1093/heapro/dar059 
132.  Anderson, E., & Shivakumar, G. (2013). Effects of exercise and physical activity 
on anxiety. Frontiers in Psychiatry, 4(APR), 10–13. doi:10.3389/fpsyt.2013.00027 
133.  Saanijoki, T., Nummenmaa, L., Eskelinen, J.-J., Savolainen, A. M., Vahlberg, T., 
Kalliokoski, K. K., & Hannukainen, J. C. (2015). Affective Responses to Repeated 
Sessions of High-Intensity Interval Training. Medicine and science in sports and 
exercise, 47(12), 2604–11. doi:10.1249/MSS.0000000000000721 
134.  Dietrich, A., & Mcdaniel, W. F. (2004). Endocannabinoids and exercise, 536–541. 
doi:10.1136/bjsm.2004.011718 
135.  Sparling, P. B., Giu, A., Piomelli, D., Rosskopf, L., & Ca, A. D. (2003). Exercise 
activates the endocannabinoid system, 14(17), 1–3. 
doi:10.1097/01.wnr.0000097048.56589.47 
136.  Heyman, E., Gamelin, F., Goekint, M., & Piscitelli, F. (2012). Intense exercise 
increases circulating endocannabinoid and BDNF levels in humans –— Possible 
implications for reward and depression. Psychoneuroendocrinology, 37(6), 844–
  
 80 
851. doi:10.1016/j.psyneuen.2011.09.017 
137.  Raichlen, D. A., Foster, A. D., & Gerdeman, G. L. (2013). Exercise-induced 
endocannabinoid signaling is modulated by intensity, 869–875. 
doi:10.1007/s00421-012-2495-5 
  
  
 81 
 
Appendices  
Appendix A – Raw Data 
1) POMS Scores 
SD
 
A
verage 
13 
12 
11 
10 
9 8 7 6 5 4 3 2 1 
Subject 
 
25.82 
32.46 
14 
74 
24 
9 
15 
27 
40 
-6 
57 
3 
72 
49 
44 
PR
E 
TM
D
 
21.87 
22.38 
5 
80 
19 
-3 
2 
18 
20 
9 
30 
9 
44 
34 
24 
PO
ST 
24.97 
21.58 
5 
78 
7 -9 
4 
14 
23 
1 
18  
49 
48 
21 
1H
PO
ST 
4.14 
6.54 
2 
10 
6 7 5 6 3 2 
10 
0 9 
14 
11 
PR
E 
Tension 
3.46 
3.85 
1 
13 
5 1 2 3 2 2 1 3 6 8 3 
PO
ST 
4.00 
3.75 
1 
11 
0 2 1 3 5 1 1  9 
10 
1 
1H
PO
ST 
5.76 
5.69 
1 
17 
2 0 4 2 5 0 
14 
0 
10 
8 
11 
PR
E 
D
epression 
  
 82 
5.98 
3.92 
0 
21 
2 0 0 0 3 0 9 0 6 3 7 
PO
ST 
6.72 
3.75 
0 
24 
2 0 0 0 2 0 5  6 4 2 
1H
PO
ST 
5.58 
4.54 
0 
20 
2 0 2 0 7 3 3 0 7 9 6 
PR
E 
A
nger 
4.65 
2.85 
0 
17 
2 0 0 0 0 3 2 0 5 3 5 
PO
ST 
5.69 
3.17 
0 
19 
3 0 0 0 0 0 0  9 3 4 
1H
PO
ST 
4.37 
5.69 
5 
10 
5 4 0 7 
10 
0 6 0 
13 
11 
3 
PR
E 
Fatigue 
4.96 
5.54 
1 
11 
5 5 0 5 3 5 1 4 7 
19 
6 
PO
ST 
5.53 
4.58 
0 
10 
3 0 0 4 2 5 0  7 
19 
5 
1H
PO
ST 
4.97 
6.69 
3 
15 
5 1 5 5 
12 
0 
10 
2 
14 
5 
10 
PR
E 
C
onfusion 
3.54 
5.31 
2 
13 
4 0 4 4 
11 
5 6 2 7 5 6 
PO
ST 
3.38 
4.83 
2 
12 
4 0 4 3 9 1 5  5 7 6 
1H
PO
ST 
  
 83 
7.34 
16.69 
17 
18 
16 
23 
21 
13 
17 
31 
6 
19 
1 
18 
17 
PR
E 
V
igour 
6.41 
19.15 
19 
16 
19 
29 
24 
14 
19 
26 
9 
20 
7 
24 
23 
PO
ST 
6.45 
18.5 
18 
18 
25 
31 
21 
16 
15 
26 
13  
7 
15 
17 
1H
PO
ST 
 
2) Blood Markers 
SD
 
A
verage 
13 
12 
11 
10 
9 8 7 6 5 4 3 2 1 
Subject 
 
1.33 
3.02 
6.17 
3.88 
2.03 
2.91 
3.70 
2.88 
2.63 
1.9 
1.51 
4.07 
2.02 
4.10 
1.52 
PR
E K
ynurenine (Pm
ol/L) 
2.64 
3.50 
6.88 
10.17 
2.93 
4.72 
2.70 
1.63 
2.06 
1.39 
3.11 
3.43 
1.50 
 
1.50 
PO
ST 
0.86 
2.69 
2.63 
2.99 
1.95 
3.57 
3.75 
3.23 
2.94 
2.00 
3.4  
1.40 
3.23 
1.17 
1H
PO
ST 
22.92 
99.93 
104.25 
93.34 
81.09 
112.37 
148.87 
111.43 
112.23 
77.42 
94.05 
88.20 
82.34 
128.73 
64.78 
PR
E Tryptophan (Pm
ol/L) 
24.20 
87.62 
115.75 
109.49 
65.52 
96.80 
127.80 
118.00 
84.59 
73.44 
67.80 
71.93 
64.34 
91.26 
52.36 
PO
ST 
26.83 
99.28 
97.35 
93.37 
80.69 
153.05 
105.15 
114.03 
116.80 
108.80 
87.01 
 
68.96 
117.70 
48.46 
1H
PO
ST 
  
 84 
3.31 
10.13 
7.34 
8.34 
8.53 
6.26 
 
6.92 
12.67 
11.09 
8.34 
13.17 
12.11 
9.11 
17.68 
PR
E 
IL-6 (pg/m
l) 
3.03 
9.51 
6.56 
8.01 
8.34 
7.26 
 
4.92 
12.35 
10.78 
8.01 
12.52 
12.11 
8.01 
15.22 
PO
ST 
2.91 
9..91 
5.82 
7.5 
8.14 
8.41 
 
10.78 
13.85 
11.72 
7.1  
11.72 
9 
14.93 
1H
PO
ST 
8.3 
25.97 
 
10.61 
14.42 
23.22 
20.56 
23.22 
25.92 
29.35 
26.91 
30.77 
40.28 
33.02 
33.26 
PR
E 
TN
F-D  (pg/m
l) 
7.91 
24.93 
 
10.9 
11.71 
23.78 
20.68 
22.11 
25.02 
30.77 
26.38 
28.45 
38.2 
30.77 
30.43 
PO
ST 
6.94 
23.17 
  
12.46 
18.66 
15.18 
21.14 
23.97 
26.31 
22.42 
 
35.48 
31.21 
24.85 
1H
PO
ST 
13.19 
40.7 
28.22 
34.43 
34.98 
36.36 
 
42.65 
24.95 
47.04 
34.25 
29.2 
61.76 
47.04 
67.47 
PR
E 
IN
F-y (pg/m
l) 
11.07 
37.63 
23.41 
28.71 
32.9 
32.7 
 
43.61 
24.65 
43.13 
33.49 
31.88 
59.78 
49.81 
47.43 
PO
ST 
11.73 
38.74 
26.65 
26.38 
31.24 
34.25 
 
41.64 
27.45 
46.03 
32.7 
 
61.66 
44.85 
53.29 
1H
PO
ST 
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Appendix B – EDSS Scores  
 
 
 Kurtzke Expanded Disability Status Scale 
(EDSS) 
 
0 Normal neurological exam (all grade 0 in Functional Systems (FS); cerebral grade 1 
acceptable).  
1 No disability, minimal signs in one FS (i.e., one grade 1 excluding cerebral grade 1). 
1.5 No disability, minimal signs in more than one FS (more than one grade 1 excluding 
cerebral grade 1). 
2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1). 
2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1). 
3.0 Moderate disability in one FS (one FS grade 3, others 0 or 1), or mild disability in three 
or four FS (three-four FS grade 2, others 0 or 1). 
3.5 Fully ambulatory but with moderate disability in one FS (one grade 3 and one or two 
FS grade 2) or two FS grade 3, others 0 or 1, or five FS grade 2, others 0 or 1. 
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite 
relatively severe disability consisting of one FS grade 4 (others 0 or 1), or combinations 
of lesser grades exceeding limits of previous steps. Able to walk without aid or rest 
some 500 meters (0.3 miles). 
4.5 Fully ambulatory without aid, up and about much of the day, able to work a full day, 
may otherwise have some limitation of full activity or require minimal assistance; 
characterized by relatively severe disability. (Usually consisting of one FS grade 4 
(others 0 or 1) or combinations of lesser grades exceeding limits of previous steps. 
Able to walk without aid or rest for some 300 meters (975 ft.).) 
5.0 Ambulatory without aid or rest for about 200 meters (650 ft.); disability severe enough 
to impair full daily activities (e.g., to work full day without special provisions). (Usual FS 
equivalents are one grade 5 alone (others 0 or 1); or combinations of lesser grades 
usually exceeding specifications for step 4.0.) 
5.5 Ambulatory without aid or rest for about 100 meters (325 ft); disability severe enough to 
impair full daily activities. (Usual FS equivalents are one grade 5 alone (others 0 or 1); 
or combinations of lesser grades usually exceeding specifications for step 4.0.) 
6.0 Intermittent or constant unilateral assistance (cane, crutch, or brace) required to walk 
about 100 meters (325 ft.) with or without resting. (Usual FS equivalents are 
combinations with more than two FS grade 3+.) 
6.5 Constant bilateral assistance (canes, crutches, or braces) required to walk about 20 
meters (65 ft.).  (Usual FS equivalents are combinations with more than two FS grade 
3+.) 
7.0 Unable to walk beyond about 5 meters (16 ft.) event with aid, essentially restricted to 
wheelchair, wheels self in standard wheelchair a full day and transfers alone; up and 
about in wheelchair some 12 hours a day. (Usual FS equivalents are combinations with 
more than one FS grade 4+; very rarely pyramidal grade 5 alone.) 
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in 
transfers, wheels self but cannot carry on in standard wheelchair a full day; may 
require motorized wheelchair. (Usual FS equivalents are combinations with more than 
one FS grade 4+.) 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair; but may be out of 
bed much of the day; retains may self-care functions; generally has effective use of 
arms. (Usual FS equivalents are combinations, generally grade 4+ in several systems.) 
8.5 Essentially restricted to bed for much of the day; has some effective use of arm(s); 
retains some self-care functions. (Usual FS equivalents are combinations, generally 
grade 4+ in several systems.) 
9.0 Helpless bed patient; can communicate and eat. (Usual FS equivalents are 
combinations, mostly grade 4.) 
9.5 Totally helpless bed patient; unable to communicate or effectively eat/swallow. (Usual 
FS equivalents are combinations, almost all grade 4+.) 
10 Death due to MS. 
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Functional Systems of the EDSS Scale 
 
Appendix C – AIS Scale 
 
 
  
  
  
  
  
  
  
  
  
Abbreviation Functional System 
BB Bowel & Bladder 
BS Brainstem 
Cb Cerebral or Mental 
C11 Cerebellar 
O Other 
P Pyramidal (motor function) 
S Sensory 
V Visual 
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Appendix D – Profile of Mood States 
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Appendix E – Ethical Approval 
 
 
 
 
 
  
Bioscience Research Ethics Board 
 
 
Certificate of Ethics Clearance for Human Participant Research 
 
Brock University 
Research Ethics Office 
Tel: 905-688-5550 ext. 3035 
Email:  reb@brocku.ca 
 
 
                    
 
DATE: 10/28/2016 
  
PRINCIPAL INVESTIGATOR: DITOR, David - Kinesiology 
  
FILE: 16-073 - DITOR 
  
TYPE: Masters Thesis/Project STUDENT: Scott Donia 
SUPERVISOR: David Ditor 
TITLE: The effects of acute aerobic exercise on mood in individuals with multiple sclerosis and incomplete 
spinal cord injury 
 
ETHICS CLEARANCE GRANTED   
Type of Clearance:  NEW Expiry Date:  10/31/2017 
 
The Brock University Bioscience Research Ethics Board has reviewed the above named research proposal and 
considers the procedures, as described by the applicant, to conform to the University’s ethical standards and the 
Tri-Council Policy Statement.  Clearance granted from 10/28/2016 to 10/31/2017.   
 
The Tri-Council Policy Statement requires that ongoing research be monitored by, at a minimum, an annual 
report.  Should your project extend beyond the expiry date, you are required to submit a Renewal form before 
10/31/2017.  Continued clearance is contingent on timely submission of reports. 
 
To comply with the Tri-Council Policy Statement, you must also submit a final report upon completion of your 
project.  All report forms can be found on the Research Ethics web page at 
http://www.brocku.ca/research/policies-and-forms/research-forms.   
 
In addition, throughout your research, you must report promptly to the REB: 
a) Changes increasing the risk to the participant(s) and/or affecting significantly the conduct of the study; 
b) All adverse and/or unanticipated experiences or events that may have real or potential unfavourable 
implications for participants; 
c) New information that may adversely affect the safety of the participants or the conduct of the study; 
d) Any changes in your source of funding or new funding to a previously unfunded project. 
 
We wish you success with your research. 
 
 
 
Approved: ________________________ 
   
  Sandra Peters, Chair 
  Bioscience Research Ethics Board  
 
Note: Brock University is accountable for the research carried out in its own jurisdiction or under its auspices 
and may refuse certain research even though the REB has found it ethically acceptable. 
 
If research participants are in the care of a health facility, at a school, or other institution or community 
organization, it is the responsibility of the Principal Investigator to ensure that the ethical guidelines and 
clearance of those facilities or institutions are obtained and filed with the REB prior to the initiation of 
research at that site. 
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Appendix F – Pilot Data  
A pilot study preceded the events of this thesis to determine the acute effects of 
aerobic exercise on mood and pain in individuals with multiple sclerosis (MS) and spinal 
cord injury (SCI). 11 participants (6 MS and 5 SCI) completed 30 minutes of moderate 
aerobic exercise. Participants maintained a cadence of 100 strides per minute, while 
altering the resistance level to sustain a 13 on a 6-20 rate of perceived exertion scale. 
Prior to exercise, participants completed 4 questionnaires and completed them again post 
exercise. Two of the questionnaires (Feeling Scale and Profile of Mood States) pertained 
to changes in mood, while the other two (Brief Pain Inventory and Neuropathic Pain 
Questionnaire) concerned changes in pain.  
Following the bout of exercise, there was a significant improvement in mood as 
shown by a reduction in the total POMS questionnaire score from pre to post-exercise 
(28.64±18.64 to 15.82±14.54, p=.01). Subscale analysis showed significant reductions in 
the Tension (4.55±3.14 to 2.82±0.75, p=.02), Depression (5.18±5.56 to 1.36±2.25, 
p=.01), Anger (4.18±4.69 to 1.45±2.46, p=.01), and Confusion 6.36±3.17 to 4.18±3.89, 
p=.04) components of the POMS from pre to post exercise. There was no change in 
Feeling Scale (3±1.34 to 3.36±1.03, p=.48) Brief Pain Inventory (3±2.22 to 2.93±2.03, 
p=.94; 2.71±2.22 to 2.51±2.17, p=.83; 2.45±2.58 to 1.91±2.12, p=.22) or Neuropathic 
Pain (14.09±13.98 to 10.87±11.59, p=.56; 25.85±26.05 to 25.34±25.56, p=.96; 
16.82±23.29 to 13.97±18.42, p=.75). This study showed that moderate intensity exercise 
was sufficient in improving mood states but not changes in pain and thus viable to 
explore potential mechanisms behind these exercise-induced alterations in mood. 
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Table #10: Pilot Participant Characteristics 
MS/SCI TYPE EDSS/ 
AISA 
SEX AGE 
(YEARS) 
YEARS 
POST 
(YEARS) 
LEVEL 
ACHEIVED 
MS SPMS 6.0 F 59 31 3 
MS SPMS 6.0 F 57 25 4 
MS RRMS 5.0 F 45 3 4 
MS RRMS 4.0 F 41 8 1 
MS SPMS 6.0 M 55 22 1 
MS SPMS 6.0 F 59 41 2 
SCI C2 D M 65 1 5 
SCI C5 D M 69 7 2 
SCI T10 A M 60 5 5 
SCI L4 D M 60 7 4 
SCI C3 D M 59 2 4 
AVE    57.2 13.8 3.2 
SD    8.0 13.6 1.5 
 
 
 
 
 
 
 
 
 
Figure #7: Pilot Profile of Mood States 
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Figure #7: Pilot Profile of Mood States 
Table #11: Pilot Feeling Scale Questionnaire 
 Pre Post Paired T-Test 
Feeling Scale 3.00±1.34 3.36±1.02 .48 
All results are shown as mean r SD. *Significantly different with P<0.05 
 
Table #12: Pilot Brief Pain Inventory 
 Pre Post Paired T-Test 
Severity 3.00±2.22 2.93±2.03 .94 
Intensity 2.71±2.22 2.51±2.17 .83 
Right Now 2.45±2.58 1.91±2.12 .22 
All results are shown as mean r SD. *Significantly different with P<0.05 
 
Table #13: Pilot Neuropathic Pain Questionnaire 
 Pre Post Paired T-Test 
Sensory 14.08±13.98 10.87±11.59 .56 
Affect 25.85±26.05 25.34±25.56 .96 
Sensitivity 16.82±23.29 13.97±18.42 .75 
All results are shown as mean r SD. *Significantly different with P<0.05 
 
 
 
 
